<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='754'><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>90</Patients><ProtocolTitle>EBA of SQ-109 in Adult Subjects with Pulmonary TB</ProtocolTitle><Trial id="71188"/><TrialEndDateActual>2012-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients><ProtocolTitle>The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects</ProtocolTitle><Trial id="139433"/><TrialEndDateActual>2013-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-06-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="52139">ofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>420</Patients><ProtocolTitle>Randomized Clinical Trial to Study the Efficacy and Tolerability of a 4-Month Regimen Containing Ofloxacin Compared to the Standard 6-Month Regimen in the Treatment of Patients with Superficial Lymphnode Tuberculosis</ProtocolTitle><Trial id="142516"/><TrialEndDateActual/><TrialEndDateCalc>2015-02-09 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-10-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Trial id="210646"/><TrialEndDateActual>2018-02-07 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-02-11 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-02-07 00:00:00</TrialEndDateGiven><TrialStartDate>2014-10-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="19980">HE-2000</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients><ProtocolTitle>A phase II pilot, placebo-controlled study to evaluate the efficacy of HE-2000 on opportunistic infections such as tuberculosis (TB) in late-stage AIDS patients</ProtocolTitle><Trial id="9820"/><TrialEndDateActual/><TrialEndDateCalc>2004-03-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2002-02-04 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>214</Patients><ProtocolTitle>Safety, Immunogenicity and Impact of MVA-85A, on the Immunogenicity of the EPI Vaccines</ProtocolTitle><Trial id="52375"/><TrialEndDateActual>2009-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-02-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>12</Patients><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously</ProtocolTitle><Trial id="10873"/><TrialEndDateActual>2005-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2005-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2005-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2003-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>A Study of two Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG</ProtocolTitle><Trial id="10944"/><TrialEndDateActual>2007-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><Trial id="100728"/><TrialEndDateActual/><TrialEndDateCalc>2014-03-24 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-01-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><Trial id="100728"/><TrialEndDateActual/><TrialEndDateCalc>2014-03-24 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-01-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53784">Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers</ProtocolTitle><Trial id="58503"/><TrialEndDateActual>2009-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>47</Patients><ProtocolTitle>A phase II, randomized, placebo-controlled study assessing the safety and efficacy of TMC-207 in patients with multidrug-resistant tuberculosis</ProtocolTitle><Trial id="57685"/><TrialEndDateActual/><TrialEndDateCalc>2011-09-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2009-06-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Trial id="210646"/><TrialEndDateActual>2018-02-07 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-02-11 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-02-07 00:00:00</TrialEndDateGiven><TrialStartDate>2014-10-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Trial id="198748"/><TrialEndDateActual>2011-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-12-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3573</Patients><ProtocolTitle>Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Healthy Adults</ProtocolTitle><Trial id="102580"/><TrialEndDateActual>2018-11-16 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-12-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-11-16 00:00:00</TrialEndDateGiven><TrialStartDate>2014-08-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57308">RUTI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>90</Patients><ProtocolTitle>Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI Following 1 Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection</ProtocolTitle><Trial id="67014"/><TrialEndDateActual>2011-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>156</Patients><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Trial id="61991"/><TrialEndDateActual>2011-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-03-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2013-10-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>71</Patients><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Trial id="87585"/><TrialEndDateActual>2017-06-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-12-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-06-28 00:00:00</TrialEndDateGiven><TrialStartDate>2013-07-13 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>23</Patients><ProtocolTitle>A phase I, controlled study to evaluate the pharmacokinetics and efficacy of PA-824 in patients with tuberculosis</ProtocolTitle><Trial id="70963"/><TrialEndDateActual/><TrialEndDateCalc>2013-01-02 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2010-09-13 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>71</Patients><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Trial id="87585"/><TrialEndDateActual>2017-06-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-12-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-06-28 00:00:00</TrialEndDateGiven><TrialStartDate>2013-07-13 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>72</Patients><ProtocolTitle>TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment</ProtocolTitle><Trial id="10847"/><TrialEndDateActual>2007-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-11-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>23</Patients><ProtocolTitle>Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia</ProtocolTitle><Trial id="10860"/><TrialEndDateActual>2006-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2006-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2006-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Trial id="10869"/><TrialEndDateActual>2007-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-06-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>98</Patients><ProtocolTitle>A Phase I/IIa Safety And Immunogenicity of AERAS-456 in HIV-Negative Adults With And Without Latent Tuberculosis Infection</ProtocolTitle><Trial id="136263"/><TrialEndDateActual>2015-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2013-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>12</Patients><ProtocolTitle>A Study to Evaluate Safety and Immunogenicity of AERAS-402</ProtocolTitle><Trial id="78482"/><TrialEndDateActual>2012-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><DevStatus id="NS">Phase not specified</DevStatus><Drug id="53724">artenimol + piperaquine (malaria), Sigma-Tau</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients</ProtocolTitle><Trial id="142485"/><TrialEndDateActual/><TrialEndDateCalc>2015-01-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2014-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2014-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>9</Patients><ProtocolTitle>Pharmacokinetics and Safety of Moxifloxacin</ProtocolTitle><Trial id="76086"/><TrialEndDateActual>2016-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-09-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2011-05-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z)</ProtocolTitle><Trial id="92275"/><TrialEndDateActual>2013-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10774">NeisVac-C</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Trial id="162886"/><TrialEndDateActual>2018-06-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-08-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-06-27 00:00:00</TrialEndDateGiven><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients><ProtocolTitle>Pharmacokinetics of efavirenz in combination of rimfampin in HIV-infected adults</ProtocolTitle><Trial id="145595"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>642</Patients><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Trial id="201474"/><TrialEndDateActual>2010-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-09-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>243</Patients><ProtocolTitle>Phase I/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants</ProtocolTitle><Trial id="134374"/><TrialEndDateActual>2017-12-22 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-10-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-12-22 00:00:00</TrialEndDateGiven><TrialStartDate>2013-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1004</Patients><ProtocolTitle>TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis</ProtocolTitle><Trial id="10650"/><TrialEndDateActual>2001-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>1997-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2001-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>1995-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>130</Patients><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Trial id="11181"/><TrialEndDateActual>2012-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11458">Menitorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Trial id="162886"/><TrialEndDateActual>2018-06-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-08-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-06-27 00:00:00</TrialEndDateGiven><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1107</Patients><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Trial id="195741"/><TrialEndDateActual>2015-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-06-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8658">rifalazil</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>A randomized, multiple-dose, open-label, phase II clinical study to evaluate the early bactericidal activity of rifalazil (PA-1648) and isoniazid (INH), as compared with INH alone or INH plus rifampin in patients with tuberculosis</ProtocolTitle><Trial id="20175"/><TrialEndDateActual/><TrialEndDateCalc>2000-02-09 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1997-10-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine</ProtocolTitle><Trial id="164024"/><TrialEndDateActual>2014-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-05-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>130</Patients><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Trial id="11181"/><TrialEndDateActual>2012-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>113</Patients><ProtocolTitle>Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection</ProtocolTitle><Trial id="201302"/><TrialEndDateActual/><TrialEndDateCalc>2017-06-23 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-01-23 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>642</Patients><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Trial id="201474"/><TrialEndDateActual>2010-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-09-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>827</Patients><ProtocolTitle>An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Trial id="153990"/><TrialEndDateActual>2012-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-12-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2008-08-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81363">AEC/BC02</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>135</Patients><ProtocolTitle>Freeze-dried recombinant tuberculosis vaccine (AEC/BC02) phase I clinical human tolerance test</ProtocolTitle><Trial id="329497"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients><ProtocolTitle>TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis</ProtocolTitle><Trial id="8751"/><TrialEndDateActual>2003-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2001-11-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2003-02-28 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2003-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>1999-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>50</Patients><ProtocolTitle>Evaluating the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection</ProtocolTitle><Trial id="250483"/><TrialEndDateActual>2019-04-10 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-06-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2019-04-10 00:00:00</TrialEndDateGiven><TrialStartDate>2017-02-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>2516</Patients><ProtocolTitle>Rifapentine-containing Tuberculosis Treatment Shortening Regimens</ProtocolTitle><Trial id="226815"/><TrialEndDateActual/><TrialEndDateCalc>2018-05-16 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-25 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="82062">ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>The Efficacy and Safety of Early Double J Stent Placement in Treatment of Renal Tuberculosis: A Novel Renal Function Protective Strategy</ProtocolTitle><Trial id="132105"/><TrialEndDateActual/><TrialEndDateCalc>2014-09-26 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-06-06 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>2516</Patients><ProtocolTitle>Rifapentine-containing Tuberculosis Treatment Shortening Regimens</ProtocolTitle><Trial id="226815"/><TrialEndDateActual/><TrialEndDateCalc>2018-05-16 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-25 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients><ProtocolTitle>Shortening Treatment by Advancing Novel Drugs</ProtocolTitle><Trial id="221844"/><TrialEndDateActual>2018-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="90085">macozinone</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>32</Patients><ProtocolTitle>Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ-169 in Multiple Dosing</ProtocolTitle><Trial id="363587"/><TrialEndDateActual/><TrialEndDateCalc>2021-06-12 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-10-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-02-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Trial id="220739"/><TrialEndDateActual>2014-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Trial id="224111"/><TrialEndDateActual/><TrialEndDateCalc>2021-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2018-12-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</ProtocolTitle><Trial id="224811"/><TrialEndDateActual>2015-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-01-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90085">macozinone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients><ProtocolTitle>Phase I Study of PBTZ-169</ProtocolTitle><Trial id="286724"/><TrialEndDateActual>2016-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11089">nitazoxanide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A 14-Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis</ProtocolTitle><Trial id="253491"/><TrialEndDateActual>2018-04-11 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-06-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-04-11 00:00:00</TrialEndDateGiven><TrialStartDate>2016-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>42</Patients><ProtocolTitle>Open, randomized, crossover study of comparative pharmacokinetics and bioequivalence of drugs Moxifloxacin tablets, film-coated, 400 mg (JSC "Pharmasyntez", Russia) and Avelox tablets, film-coated, 400 mg ("Bayer Pharma AG", Germany)</ProtocolTitle><Trial id="247038"/><TrialEndDateActual/><TrialEndDateCalc>2017-05-26 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-10-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-10-01 00:00:00</TrialEndDateGiven><TrialStartDate>2015-11-23 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>592</Patients><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Trial id="8820"/><TrialEndDateActual/><TrialEndDateCalc>2011-11-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="87251">Perchlozone</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>120</Patients><ProtocolTitle>An Open, Prospective, Comparative, Randomized, Controlled Clinical Trial Of Efficacy And Safety Perhlozone Capsules (JSC 'Pharmasyntez', Russia), Used In Doses Of 9.5 And 12.5 mg/kg Night In The Complex Treatment Of Pulmonary Tuberculosis</ProtocolTitle><Trial id="169098"/><TrialEndDateActual/><TrialEndDateCalc>2015-05-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2014-10-09 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2014-10-09 00:00:00</TrialEndDateGiven><TrialStartDate>2013-01-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>419</Patients><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Trial id="280225"/><TrialEndDateActual>2018-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-04-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>640</Patients><ProtocolTitle>Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis</ProtocolTitle><Trial id="293087"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-26 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-10-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-10-01 00:00:00</TrialEndDateGiven><TrialStartDate>2018-02-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>62</Patients><ProtocolTitle>PK Study of Rifampicin Interactions With DMPA and Efaviranz in TB</ProtocolTitle><Trial id="227340"/><TrialEndDateActual>2017-06-15 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-04-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-06-15 00:00:00</TrialEndDateGiven><TrialStartDate>2015-11-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71323">Ad5Ag85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>Phase I Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol</ProtocolTitle><Trial id="219950"/><TrialEndDateActual/><TrialEndDateCalc>2019-12-26 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-09-05 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>155</Patients><ProtocolTitle>Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children</ProtocolTitle><Trial id="37985"/><TrialEndDateActual>2016-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-01-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients><ProtocolTitle>Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB (rhIL-2)</ProtocolTitle><Trial id="289837"/><TrialEndDateActual/><TrialEndDateCalc>2011-09-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-03-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-03-01 00:00:00</TrialEndDateGiven><TrialStartDate>2009-06-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients><ProtocolTitle>A Phase II, Multicenter, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683</ProtocolTitle><Trial id="242789"/><TrialEndDateActual>2011-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-07-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Trial id="259506"/><TrialEndDateActual/><TrialEndDateCalc>2019-04-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44437">verapamil</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>69</Patients><ProtocolTitle>Verapamil Dose-finding Study in Adult Patients with Tuberculosis</ProtocolTitle><Trial id="261260"/><TrialEndDateActual/><TrialEndDateCalc>2018-10-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2016-06-15 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>460</Patients><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Trial id="214156"/><TrialEndDateActual/><TrialEndDateCalc>2018-02-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>69</Patients><ProtocolTitle>Phase IIa Evaluation of Early Bactericidal Activity of PA-824 in Pulmonary Tuberculosis</ProtocolTitle><Trial id="9381"/><TrialEndDateActual>2007-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="6050">metformin hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Effect of metformin on sputum smear conversion in pulmonary tuberculosis with type 2 diabetes mellitus</ProtocolTitle><Trial id="370128"/><TrialEndDateActual/><TrialEndDateCalc>2021-06-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-03-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>6</Patients><ProtocolTitle>A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects</ProtocolTitle><Trial id="303299"/><TrialEndDateActual>2006-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>419</Patients><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Trial id="280225"/><TrialEndDateActual>2018-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-04-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>62</Patients><ProtocolTitle>A phase Ia, Placebo-controlled, Dose-Escalating study to test the Safety, Tolerability and Pharmacokinetics of Single dose of SQ-109 in 62 Healthy Subjects</ProtocolTitle><Trial id="8945"/><TrialEndDateActual>2007-05-03 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-01-19 16:46:54</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-05-03 00:00:00</TrialEndDateGiven><TrialStartDate>2006-09-30 04:46:54</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Trial id="360104"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-08-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-08-01 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-02 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Trial id="360104"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-08-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-08-01 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-02 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>630</Patients><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Trial id="244304"/><TrialEndDateActual/><TrialEndDateCalc>2019-05-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12420">rosuvastatin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>50</Patients><ProtocolTitle>Effect of rosuvastatin on HIV TB coinfection</ProtocolTitle><Trial id="292154"/><TrialEndDateActual/><TrialEndDateCalc>2019-06-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2017-04-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB</ProtocolTitle><Trial id="228651"/><TrialEndDateActual>2010-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2587">azithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy</ProtocolTitle><Trial id="8647"/><TrialEndDateActual/><TrialEndDateCalc>2002-01-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1999-11-02 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Trial id="369109"/><TrialEndDateActual/><TrialEndDateCalc>2021-06-27 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-03-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>31</Patients><ProtocolTitle>Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis</ProtocolTitle><Trial id="261481"/><TrialEndDateActual>2018-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-02-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-11-04 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Prospective, Randomized Control, Non-inferiority Study of the Use of Faropenem for Patients with etiology Positive Pulmonary Tuberculosis</ProtocolTitle><Trial id="338648"/><TrialEndDateActual/><TrialEndDateCalc>2020-09-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-05-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-05-01 00:00:00</TrialEndDateGiven><TrialStartDate>2018-05-15 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70581">GSK-3036656</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK-3036656 in Healthy Subjects</ProtocolTitle><Trial id="290705"/><TrialEndDateActual>2017-08-04 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-07-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-08-04 00:00:00</TrialEndDateGiven><TrialStartDate>2017-04-02 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>167</Patients><ProtocolTitle>A prospective, unblinded, non-randomized, single-center study to evaluate outcomes of bedaquiline-included regimens in multidrug-resistance/extensively drug-resistant (MDR/XDR) tuberculosis patients after 24 months and to identify factors predisposing the long-term treatment success</ProtocolTitle><Trial id="361163"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2587">azithromycin</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis</ProtocolTitle><Trial id="298743"/><TrialEndDateActual/><TrialEndDateCalc>2020-05-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2018-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>38</Patients><ProtocolTitle>Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-Positive Adults</ProtocolTitle><Trial id="9528"/><TrialEndDateActual>2006-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-11-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase II trial to evaluate delamanid in pediatric patients with multi-drug resistance tuberculosis</ProtocolTitle><Trial id="341287"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2587">azithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Trial id="379769"/><TrialEndDateActual/><TrialEndDateCalc>2021-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-07-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Trial id="375499"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1802</Patients><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65 years (III-healthy)</ProtocolTitle><Trial id="262931"/><TrialEndDateActual>2016-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-09-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53784">Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>240</Patients><ProtocolTitle>THYB-04</ProtocolTitle><Trial id="285704"/><TrialEndDateActual/><TrialEndDateCalc>2014-12-17 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-08-27 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="22216">etoricoxib</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients><ProtocolTitle>Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic</ProtocolTitle><Trial id="235355"/><TrialEndDateActual/><TrialEndDateCalc>2018-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="26574">lamivudine + abacavir + zidovudine, GSK</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>350</Patients><ProtocolTitle>Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis</ProtocolTitle><Trial id="8801"/><TrialEndDateActual/><TrialEndDateCalc>2007-01-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>113</Patients><ProtocolTitle>Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection</ProtocolTitle><Trial id="201302"/><TrialEndDateActual/><TrialEndDateCalc>2017-06-23 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-01-23 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="104447">OPC-167832</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A phase I, single-ascending-dose study of OPC-167832 for the treatment of Mycobacterium tuberculosis infection</ProtocolTitle><Trial id="327014"/><TrialEndDateActual>2017-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven>2017-12-31 00:00:00</TrialEndDateGiven><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>900</Patients><ProtocolTitle>Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence</ProtocolTitle><Trial id="337957"/><TrialEndDateActual/><TrialEndDateCalc>2021-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>74</Patients><ProtocolTitle>A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371</ProtocolTitle><Trial id="303756"/><TrialEndDateActual>2018-07-08 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-12-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-07-08 00:00:00</TrialEndDateGiven><TrialStartDate>2017-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>152</Patients><ProtocolTitle>Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide</ProtocolTitle><Trial id="183613"/><TrialEndDateActual/><TrialEndDateCalc>2016-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>160</Patients><ProtocolTitle>Is Levofloxacin Better Than Rifampicin in the Treatment of Tuberculous Meningitis- a Randomized, Control Study</ProtocolTitle><Trial id="129005"/><TrialEndDateActual/><TrialEndDateCalc>2012-01-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2009-10-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Trial id="76946"/><TrialEndDateActual/><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2013-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2013-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients><ProtocolTitle>Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid</ProtocolTitle><Trial id="265766"/><TrialEndDateActual/><TrialEndDateCalc>2019-03-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-02-28 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Trial id="76946"/><TrialEndDateActual/><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2013-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2013-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA-85A in BCG-vaccinated African Adolescents</ProtocolTitle><Trial id="201409"/><TrialEndDateActual>2015-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>642</Patients><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Trial id="201474"/><TrialEndDateActual>2010-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-09-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>71</Patients><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Trial id="87585"/><TrialEndDateActual>2017-06-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-12-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-06-28 00:00:00</TrialEndDateGiven><TrialStartDate>2013-07-13 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients><ProtocolTitle>Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz</ProtocolTitle><Trial id="10657"/><TrialEndDateActual>2004-02-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2002-02-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2004-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2004-02-01 00:00:00</TrialEndDateGiven><TrialStartDate>1999-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>A randomized, open, balanced, two-component, two-period, crossover, with a single-dose study of comparative pharmacokinetics and bioequivalence of Primflo (moxifloxacin) 400 mg (Dr Reddy's Laboratories Ltd, India) and Avilox  (moxifloxacin) 400 mg (Bayer Healthcare AG, Germany), when taken orally on an empty stomach in healthy adult volunteers</ProtocolTitle><Trial id="167750"/><TrialEndDateActual/><TrialEndDateCalc>2014-04-13 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2014-09-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2014-09-01 00:00:00</TrialEndDateGiven><TrialStartDate>2012-10-10 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Trial id="76946"/><TrialEndDateActual/><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2013-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2013-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>48</Patients><ProtocolTitle>Study to Evaluate Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Newborn Infants in South Africa</ProtocolTitle><Trial id="82764"/><TrialEndDateActual>2012-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>520</Patients><ProtocolTitle>A multicenter, randomized, 6-month study to compare the efficacy, tolerability and toxicity of two different regimens of rifabutin with that of rifampicin</ProtocolTitle><Trial id="15869"/><TrialEndDateActual/><TrialEndDateCalc>1997-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1994-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients><ProtocolTitle>TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)</ProtocolTitle><Trial id="56959"/><TrialEndDateActual>2010-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-11-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients><ProtocolTitle>PNU-100480 In Newly Diagnosed, Treatment Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay</ProtocolTitle><Trial id="71511"/><TrialEndDateActual>2011-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2011-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>68</Patients><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis</ProtocolTitle><Trial id="71046"/><TrialEndDateActual>2010-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>48</Patients><ProtocolTitle>A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA-85A</ProtocolTitle><Trial id="69926"/><TrialEndDateActual>2012-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-09-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="5321">indinavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin</ProtocolTitle><Trial id="10871"/><TrialEndDateActual>2009-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-03-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2009-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2009-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>433</Patients><ProtocolTitle>TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment</ProtocolTitle><Trial id="10685"/><TrialEndDateActual>2007-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71323">Ad5Ag85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine</ProtocolTitle><Trial id="77668"/><TrialEndDateActual>2013-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>48</Patients><ProtocolTitle>A Study of MVA-85A, in Asymptomatic Volunteers Infected With TB, HIV or Both</ProtocolTitle><Trial id="14589"/><TrialEndDateActual>2011-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-10-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="6242">abacavir</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Trial id="63729"/><TrialEndDateActual/><TrialEndDateCalc>2013-01-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>529</Patients><ProtocolTitle>Rifapentine During Intensive Phase Tuberculosis (TB) Treatment</ProtocolTitle><Trial id="17237"/><TrialEndDateActual>2013-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-04-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>7</Patients><ProtocolTitle>Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients</ProtocolTitle><Trial id="182646"/><TrialEndDateActual>2012-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-04-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Phase IIb Clinical Study of new GSK Vaccine Candidate</ProtocolTitle><Trial id="137219"/><TrialEndDateActual/><TrialEndDateCalc>2015-04-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2013-01-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>88</Patients><ProtocolTitle>TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions</ProtocolTitle><Trial id="74529"/><TrialEndDateActual>2011-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Trial id="150793"/><TrialEndDateActual>2017-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2013-08-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>113</Patients><ProtocolTitle>A Phase II Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients</ProtocolTitle><Trial id="215072"/><TrialEndDateActual>2017-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2014-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>570</Patients><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Trial id="10948"/><TrialEndDateActual>2011-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-03-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2011-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study</ProtocolTitle><Trial id="67996"/><TrialEndDateActual>2012-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-02-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>182</Patients><ProtocolTitle>Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients</ProtocolTitle><Trial id="63801"/><TrialEndDateActual>2012-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2012-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2012-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>295</Patients><ProtocolTitle>Early Access of TMC-207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis</ProtocolTitle><Trial id="82132"/><TrialEndDateActual/><TrialEndDateCalc>2014-01-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2011-09-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>101</Patients><ProtocolTitle>A phase I, randomized, study to evaluate the efficacy of SRL-172 on cell-mediated immunity of patients with pulmonary tuberculosis</ProtocolTitle><Trial id="17288"/><TrialEndDateActual/><TrialEndDateCalc>2002-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>6</Patients><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Trial id="222400"/><TrialEndDateActual>2018-11-08 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-05-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-11-08 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>540</Patients><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Trial id="145651"/><TrialEndDateActual>2010-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>5</Patients><ProtocolTitle>A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV</ProtocolTitle><Trial id="11177"/><TrialEndDateActual>2008-03-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-10-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2008-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2008-03-01 00:00:00</TrialEndDateGiven><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>570</Patients><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Trial id="10948"/><TrialEndDateActual>2011-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-03-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2011-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients><ProtocolTitle>A Clinical Challenge Study of BCG in Healthy Volunteers</ProtocolTitle><Trial id="177982"/><TrialEndDateActual>2015-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="49162">LL-3858</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>A phase IIa clinical trial for a novel molecule (LL-3858) developed by Lupin Limited which has the potential of treating the Pulmonary tuberculosis patients effectively</ProtocolTitle><Trial id="103573"/><TrialEndDateActual/><TrialEndDateCalc>2012-03-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2009-12-02 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>2000</Patients><ProtocolTitle>A five year study to evaluate the safety and efficacy of SRL-172 in the prevention of tuberculosis in HIV-positive subjects</ProtocolTitle><Trial id="19967"/><TrialEndDateActual/><TrialEndDateCalc>2003-12-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2001-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>63</Patients><ProtocolTitle>Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment</ProtocolTitle><Trial id="169697"/><TrialEndDateActual>2011-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2011-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients><ProtocolTitle>TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)</ProtocolTitle><Trial id="56959"/><TrialEndDateActual>2010-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-11-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Moxifloxacin_QT Study in Chinese Healthy Volunteer</ProtocolTitle><Trial id="89715"/><TrialEndDateActual/><TrialEndDateCalc>2014-02-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2012-10-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2012-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>145</Patients><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Trial id="10947"/><TrialEndDateActual>2010-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>74</Patients><ProtocolTitle>Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers</ProtocolTitle><Trial id="90512"/><TrialEndDateActual>2012-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>114</Patients><ProtocolTitle>Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease</ProtocolTitle><Trial id="90788"/><TrialEndDateActual/><TrialEndDateCalc>2015-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2014-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2014-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients><ProtocolTitle>Interaction Between High-Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection</ProtocolTitle><Trial id="161096"/><TrialEndDateActual/><TrialEndDateCalc>2016-03-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2017-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2017-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients><ProtocolTitle>Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment</ProtocolTitle><Trial id="182316"/><TrialEndDateActual>2013-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-01-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients><ProtocolTitle>Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine</ProtocolTitle><Trial id="10943"/><TrialEndDateActual>2008-08-24 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-08-24 00:00:00</TrialEndDateGiven><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>365</Patients><ProtocolTitle>Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design</ProtocolTitle><Trial id="109063"/><TrialEndDateActual>2015-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90231">DAR-901</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients><ProtocolTitle>Phase I Trial of DAR-901</ProtocolTitle><Trial id="173446"/><TrialEndDateActual>2016-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients><ProtocolTitle>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</ProtocolTitle><Trial id="68204"/><TrialEndDateActual>2011-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>283</Patients><ProtocolTitle>Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter, Randomized, Controlled Study in Taiwan</ProtocolTitle><Trial id="207608"/><TrialEndDateActual/><TrialEndDateCalc>2016-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2014-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12132">albendazole</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients><ProtocolTitle>Tuberculosis - Learning the Impact of Nutrition</ProtocolTitle><Trial id="347635"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1148</Patients><ProtocolTitle>Tuberculosis Prevention for HIV Infected Adults</ProtocolTitle><Trial id="8790"/><TrialEndDateActual>2009-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2005-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2002-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients><ProtocolTitle>Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid</ProtocolTitle><Trial id="303595"/><TrialEndDateActual>2017-12-16 00:00:00</TrialEndDateActual><TrialEndDateCalc>2020-01-16 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-12-16 00:00:00</TrialEndDateGiven><TrialStartDate>2017-09-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients><ProtocolTitle>Taima TB: 3-HP Study</ProtocolTitle><Trial id="254050"/><TrialEndDateActual/><TrialEndDateCalc>2018-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Trial id="260814"/><TrialEndDateActual/><TrialEndDateCalc>2018-08-09 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-06-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="76307">delpazolid</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A clinical trial of RMX-2001 in multidrug-resistant tuberculosis (MDR-TB) in China</ProtocolTitle><Trial id="370697"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>80</Patients><ProtocolTitle>Research on New Regimens for Retreatment Pulmonary Tuberculosis</ProtocolTitle><Trial id="220243"/><TrialEndDateActual/><TrialEndDateCalc>2015-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>530</Patients><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Trial id="228190"/><TrialEndDateActual/><TrialEndDateCalc>2018-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Trial id="230529"/><TrialEndDateActual/><TrialEndDateCalc>2018-02-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>460</Patients><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Trial id="214156"/><TrialEndDateActual/><TrialEndDateCalc>2018-02-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>419</Patients><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Trial id="280225"/><TrialEndDateActual>2018-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-04-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients><ProtocolTitle>A 9-Month Isoniazid versus 3-Month Isoniazid plus Rifapentine for Treatment of Tuberculosis Infection in Rheumatic Patients: a Randomized, Controlled Trial</ProtocolTitle><Trial id="352748"/><TrialEndDateActual/><TrialEndDateCalc>2019-12-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-09-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46931">cefadroxil</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Trial id="224111"/><TrialEndDateActual/><TrialEndDateCalc>2021-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2018-12-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Trial id="259506"/><TrialEndDateActual/><TrialEndDateCalc>2019-04-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Trial id="244777"/><TrialEndDateActual/><TrialEndDateCalc>2011-01-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2010-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-10-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Trial id="334027"/><TrialEndDateActual/><TrialEndDateCalc>2020-08-28 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-04-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>RIFART</ProtocolTitle><Trial id="131240"/><TrialEndDateActual>2011-04-19 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-05-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-19 00:00:00</TrialEndDateGiven><TrialStartDate>2005-03-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>488</Patients><ProtocolTitle>NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB</ProtocolTitle><Trial id="348056"/><TrialEndDateActual/><TrialEndDateCalc>2020-11-24 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2024-08-04 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2024-08-04 00:00:00</TrialEndDateGiven><TrialStartDate>2018-08-05 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="108779">GC-3107</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>Study to Investigate the Safety and Efficacy of GC-3107 (BCG Vaccine) in Healthy Adults</ProtocolTitle><Trial id="321760"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-12-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>A Comparative study of different treatment regimes for brain tuberculosis</ProtocolTitle><Trial id="382387"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-15 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-05-27 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>15</Patients><ProtocolTitle>A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects</ProtocolTitle><Trial id="25327"/><TrialEndDateActual>2008-10-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-11-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-10-01 00:00:00</TrialEndDateGiven><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>183</Patients><ProtocolTitle>Assessing PA-824 for Tuberculosis</ProtocolTitle><Trial id="213394"/><TrialEndDateActual/><TrialEndDateCalc>2017-08-18 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-04-29 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Trial id="220739"/><TrialEndDateActual>2014-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Trial id="368916"/><TrialEndDateActual/><TrialEndDateCalc>2022-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2020-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>84</Patients><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Trial id="243619"/><TrialEndDateActual/><TrialEndDateCalc>2019-01-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-01-15 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-01-15 00:00:00</TrialEndDateGiven><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso</ProtocolTitle><Trial id="161441"/><TrialEndDateActual/><TrialEndDateCalc>2016-04-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2014-11-27 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2014-11-27 00:00:00</TrialEndDateGiven><TrialStartDate>2013-11-28 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>2500</Patients><ProtocolTitle>Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349)</ProtocolTitle><Trial id="347338"/><TrialEndDateActual/><TrialEndDateCalc>2020-11-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2018-07-20 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>630</Patients><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Trial id="244304"/><TrialEndDateActual/><TrialEndDateCalc>2019-05-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="61340">S-004992</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase I study to evaluate S-004992 in patients with tuberculosis</ProtocolTitle><Trial id="348025"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>Pharmacokinetic study and safety of levofloxacin in pediatric tuberculosis treatment</ProtocolTitle><Trial id="381490"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-31 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-05-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-05-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Trial id="8644"/><TrialEndDateActual>2008-04-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-04-01 00:00:00</TrialEndDateGiven><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Trial id="280651"/><TrialEndDateActual/><TrialEndDateCalc>2019-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2017-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>238</Patients><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Trial id="247456"/><TrialEndDateActual/><TrialEndDateCalc>2018-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients><ProtocolTitle>A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin</ProtocolTitle><Trial id="8780"/><TrialEndDateActual/><TrialEndDateCalc>2002-01-07 06:30:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1999-11-01 18:30:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Trial id="368916"/><TrialEndDateActual/><TrialEndDateCalc>2022-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2020-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="6229">Infanrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Trial id="162886"/><TrialEndDateActual>2018-06-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-08-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-06-27 00:00:00</TrialEndDateGiven><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Trial id="259506"/><TrialEndDateActual/><TrialEndDateCalc>2019-04-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Trial id="368916"/><TrialEndDateActual/><TrialEndDateCalc>2022-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2020-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>110</Patients><ProtocolTitle>Safety and Immunogenicity of Two Formulations of Tuberculosis Vaccines GSK-692342 Given at 0, 1 Months to Healthy Adults</ProtocolTitle><Trial id="9520"/><TrialEndDateActual>2007-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Trial id="360329"/><TrialEndDateActual/><TrialEndDateCalc>2021-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-05-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-05-30 00:00:00</TrialEndDateGiven><TrialStartDate>2018-11-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>180</Patients><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Trial id="293734"/><TrialEndDateActual/><TrialEndDateCalc>2020-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>250</Patients><ProtocolTitle>Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis</ProtocolTitle><Trial id="374838"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>488</Patients><ProtocolTitle>NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB</ProtocolTitle><Trial id="348056"/><TrialEndDateActual/><TrialEndDateCalc>2020-11-24 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2024-08-04 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2024-08-04 00:00:00</TrialEndDateGiven><TrialStartDate>2018-08-05 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>14</Patients><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA-85A Vaccine in Healthy Volunteers</ProtocolTitle><Trial id="9320"/><TrialEndDateActual>2003-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2005-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2003-07-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2003-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2002-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Trial id="369109"/><TrialEndDateActual/><TrialEndDateCalc>2021-06-27 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-03-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>80</Patients><ProtocolTitle>Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Healthy Male Volunteers</ProtocolTitle><Trial id="48943"/><TrialEndDateActual>2009-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>19</Patients><ProtocolTitle>Safety, Tolerability And Pharmacokinetics Study Of Single-Doses Of PNU-100480 In Healthy Adults</ProtocolTitle><Trial id="50188"/><TrialEndDateActual>2009-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>827</Patients><ProtocolTitle>An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Trial id="153990"/><TrialEndDateActual>2012-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-12-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2008-08-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>101</Patients><ProtocolTitle>Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB</ProtocolTitle><Trial id="149562"/><TrialEndDateActual/><TrialEndDateCalc>2017-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-01-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen</ProtocolTitle><Trial id="10648"/><TrialEndDateActual/><TrialEndDateCalc>2003-09-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2001-07-02 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Trial id="150793"/><TrialEndDateActual>2017-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2013-08-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>130</Patients><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Trial id="11181"/><TrialEndDateActual>2012-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients><ProtocolTitle>An Open-Label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Haynemoks, 400 mg (Hayglans Laboratories Pvt. Ltd., India) and Avelox, 400 mg (Bayer Healthcare AG, Germany) in Healthy Volunteers</ProtocolTitle><Trial id="168898"/><TrialEndDateActual/><TrialEndDateCalc>2014-05-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2013-07-05 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2013-07-05 00:00:00</TrialEndDateGiven><TrialStartDate>2012-10-29 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12862">Tritanrix HB</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>302</Patients><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Trial id="65639"/><TrialEndDateActual>2012-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-11-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients><ProtocolTitle>Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults</ProtocolTitle><Trial id="62096"/><TrialEndDateActual>2012-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1836</Patients><ProtocolTitle>A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Trial id="10855"/><TrialEndDateActual/><TrialEndDateCalc>2007-05-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2005-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients><ProtocolTitle>Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single-Dose or in Divided Doses to Healthy Adults</ProtocolTitle><Trial id="86389"/><TrialEndDateActual>2013-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-09-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>50</Patients><ProtocolTitle>A single-blind, randomized, safety study comparing rifabutin with rifampicin in the treatment of HIV-1-associated tuberculosis</ProtocolTitle><Trial id="15878"/><TrialEndDateActual/><TrialEndDateCalc>1998-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1995-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>65</Patients><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Trial id="71107"/><TrialEndDateActual>2011-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-02-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Phase I ID-93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers</ProtocolTitle><Trial id="87507"/><TrialEndDateActual>2014-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Intramuscular Route and the Intradermal Route</ProtocolTitle><Trial id="69212"/><TrialEndDateActual>2011-01-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-01-01 00:00:00</TrialEndDateGiven><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Trial id="86312"/><TrialEndDateActual>2013-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-09-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25023">golotimod</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients><ProtocolTitle>Phase II Trial of SCV-07 in TB</ProtocolTitle><Trial id="144312"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>Comparison of Sputum Conversion Rates, Plasma Rifampicin Levels and Cyp 450 Activity Pulmonary Tuberculosis Patients Have Received 8 Weeks of Intensive Phase Therapy With Standard Dose Regimen Versus Risorine Kit</ProtocolTitle><Trial id="142231"/><TrialEndDateActual/><TrialEndDateCalc>2014-09-30 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-06-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>50</Patients><ProtocolTitle>A Risorine Study in Sputum Positive Patients After 8 Weeks of Conventional Treatment</ProtocolTitle><Trial id="138715"/><TrialEndDateActual/><TrialEndDateCalc>2014-09-30 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-06-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>350</Patients><ProtocolTitle>TBTC Study 27: Moxifloxacin versus Ethambutol for TB Treatment</ProtocolTitle><Trial id="10684"/><TrialEndDateActual>2005-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2005-11-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2005-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Trial id="86312"/><TrialEndDateActual>2013-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-09-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Bioavailability</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Trial id="136052"/><TrialEndDateActual/><TrialEndDateCalc>2008-08-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2006-05-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Trial id="10869"/><TrialEndDateActual>2007-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-06-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>570</Patients><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Trial id="10948"/><TrialEndDateActual>2011-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-03-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2011-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44305">omeprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Trial id="122291"/><TrialEndDateActual>2011-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Aerosol Route and the Intradermal Route</ProtocolTitle><Trial id="83464"/><TrialEndDateActual>2013-04-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-04-01 00:00:00</TrialEndDateGiven><TrialStartDate>2011-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>48</Patients><ProtocolTitle>A phase IIa, open-label, safety and immunogenicity study of MVA-85A in HIV- and/or Mycobacterium tuberculosis-infected adults</ProtocolTitle><Trial id="86807"/><TrialEndDateActual/><TrialEndDateCalc>2013-12-15 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2011-08-26 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients><ProtocolTitle>An open-label, comparative, multicenter trial to evaluate long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis</ProtocolTitle><Trial id="113726"/><TrialEndDateActual/><TrialEndDateCalc>2005-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2003-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>204</Patients><ProtocolTitle>A Randomized, Double-blind, Multicenter, Placebo-controlled Trial to Study the Efficacy of Mycobacterium vaccae Immunotherapy for Tuberculosis in KwaZulu, South Africa, 1991-97</ProtocolTitle><Trial id="109626"/><TrialEndDateActual/><TrialEndDateCalc>2003-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3365">Actimmune</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase III study to evaluate the safety and efficacy of aerosolized Actimmune for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB) in patients who have failed a treatment regimen of anti-tuberculosis therapy</ProtocolTitle><Trial id="14945"/><TrialEndDateActual/><TrialEndDateCalc>2002-11-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-08-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>481</Patients><ProtocolTitle>A Placebo-Controlled, Phase II Trial to Evaluate OPC-67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-Resistant Tuberculosis (TB)</ProtocolTitle><Trial id="15754"/><TrialEndDateActual>2010-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>RIFART</ProtocolTitle><Trial id="131240"/><TrialEndDateActual>2011-04-19 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-05-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-19 00:00:00</TrialEndDateGiven><TrialStartDate>2005-03-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>493</Patients><ProtocolTitle>Optimization of Tuberculosis and HIV Co-treatment in Africa</ProtocolTitle><Trial id="131419"/><TrialEndDateActual/><TrialEndDateCalc>2010-03-16 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2008-01-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Trial id="10869"/><TrialEndDateActual>2007-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-06-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="28379">Glutoxim</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>42</Patients><ProtocolTitle>Glutoxim in the Complex Treatment of Tuberculosis</ProtocolTitle><Trial id="149460"/><TrialEndDateActual>2002-01-01 00:00:00</TrialEndDateActual><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven>2002-01-01 00:00:00</TrialEndDateGiven><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="98373">TB/FLU-04L</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine</ProtocolTitle><Trial id="235054"/><TrialEndDateActual>2015-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>145</Patients><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Trial id="10947"/><TrialEndDateActual>2010-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients><ProtocolTitle>Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers</ProtocolTitle><Trial id="60906"/><TrialEndDateActual>2010-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>416</Patients><ProtocolTitle>Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB</ProtocolTitle><Trial id="150332"/><TrialEndDateActual/><TrialEndDateCalc>2006-09-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2004-05-14 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="5369">ribavirin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>550</Patients><ProtocolTitle>Antivirus Therapy for Population with HIV, HCV and TB Co-infection Clinical Trial</ProtocolTitle><Trial id="162528"/><TrialEndDateActual/><TrialEndDateCalc>2011-05-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2009-05-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>145</Patients><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Trial id="10947"/><TrialEndDateActual>2010-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC-207 in Treatment of Pulmonary Tuberculosis</ProtocolTitle><Trial id="150059"/><TrialEndDateActual>2008-08-01 00:00:00</TrialEndDateActual><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven>2008-08-01 00:00:00</TrialEndDateGiven><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults</ProtocolTitle><Trial id="142322"/><TrialEndDateActual>2014-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-11-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>37</Patients><ProtocolTitle>Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA-85A, as a Way to Increase Immune Response and Avoid Anti-Vector Immunity</ProtocolTitle><Trial id="156675"/><TrialEndDateActual>2015-02-02 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-02-02 00:00:00</TrialEndDateGiven><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>63</Patients><ProtocolTitle>Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment</ProtocolTitle><Trial id="169697"/><TrialEndDateActual>2011-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2011-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1650</Patients><ProtocolTitle>A Clinical Trial to Study the Effectiveness and Safety of 3- and 4-Month Regimens as Compared to the Standard 6-Month Regimen for the Treatment of Infectious Pulmonary Tuberculosis Patients</ProtocolTitle><Trial id="121916"/><TrialEndDateActual/><TrialEndDateCalc>2009-09-18 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2007-05-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3000</Patients><ProtocolTitle>Brief Rifapentine-Isoniazid Evaluation for TB Prevention</ProtocolTitle><Trial id="79741"/><TrialEndDateActual>2017-11-14 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-09-12 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-11-14 00:00:00</TrialEndDateGiven><TrialStartDate>2012-05-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients><ProtocolTitle>Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-Endemic Region</ProtocolTitle><Trial id="11563"/><TrialEndDateActual>2008-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-06-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis Vaccine in Healthy HIV Negative Adolescents</ProtocolTitle><Trial id="59304"/><TrialEndDateActual>2010-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>43</Patients><ProtocolTitle>A comparative, open-labeled, randomized study to evaluate the bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis</ProtocolTitle><Trial id="114922"/><TrialEndDateActual/><TrialEndDateCalc>2006-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2003-12-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>156</Patients><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Trial id="61991"/><TrialEndDateActual>2011-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-03-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2013-10-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3738</Patients><ProtocolTitle>Intervention study in rural residents (50 to 70 years old) with latent Mycobacterium tuberculosis infection</ProtocolTitle><Trial id="243294"/><TrialEndDateActual/><TrialEndDateCalc>2016-04-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2014-01-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="81363">AEC/BC02</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A Phase III trial of recombinant tuberculosis vaccine AEC/BC02 in patients with tuberculosis</ProtocolTitle><Trial id="352354"/><TrialEndDateActual>2018-09-03 00:00:00</TrialEndDateActual><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven>2018-09-03 00:00:00</TrialEndDateGiven><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1002</Patients><ProtocolTitle>Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT</ProtocolTitle><Trial id="177457"/><TrialEndDateActual>2014-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="87251">Perchlozone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>An open, phase I study to study the pharmacokinetics, safety and tolerability of Perhlozone (400 mg capsules) in healthy volunteers after a single dose</ProtocolTitle><Trial id="167779"/><TrialEndDateActual/><TrialEndDateCalc>2014-07-10 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2013-01-13 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2013-01-13 00:00:00</TrialEndDateGiven><TrialStartDate>2012-03-20 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><DevStatus id="NS">Phase not specified</DevStatus><Drug id="53041">artesunate + amodiaquine combination tablet (malaria), DNDi/sanofi-aventis</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients</ProtocolTitle><Trial id="142485"/><TrialEndDateActual/><TrialEndDateCalc>2015-01-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2014-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2014-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, RIN-150 And Individual Reference Drugs In Healthy Volunteers</ProtocolTitle><Trial id="164292"/><TrialEndDateActual>2012-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Trial id="329251"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-11-03 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-11-03 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71742">TBA-354</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>18</Patients><ProtocolTitle>A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</ProtocolTitle><Trial id="246089"/><TrialEndDateActual/><TrialEndDateCalc>2018-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>6</Patients><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Trial id="222400"/><TrialEndDateActual>2018-11-08 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-05-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-11-08 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Phase I Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent</ProtocolTitle><Trial id="366672"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-02 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>88</Patients><ProtocolTitle>Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB</ProtocolTitle><Trial id="300655"/><TrialEndDateActual/><TrialEndDateCalc>2019-12-13 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-07-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-08-23 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>109</Patients><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Trial id="219499"/><TrialEndDateActual/><TrialEndDateCalc>2017-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-10-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="6050">metformin hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>316</Patients><ProtocolTitle>Metformin in tuberculosis</ProtocolTitle><Trial id="325158"/><TrialEndDateActual/><TrialEndDateCalc>2021-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2018-11-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>530</Patients><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Trial id="228190"/><TrialEndDateActual/><TrialEndDateCalc>2018-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients><ProtocolTitle>Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</ProtocolTitle><Trial id="384080"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="57308">RUTI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>27</Patients><ProtocolTitle>Safety of RUTI Vaccination in MDR-TB Patients</ProtocolTitle><Trial id="256039"/><TrialEndDateActual/><TrialEndDateCalc>2021-04-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-07-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-01-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>84</Patients><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Trial id="243619"/><TrialEndDateActual/><TrialEndDateCalc>2019-01-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-01-15 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-01-15 00:00:00</TrialEndDateGiven><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>630</Patients><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Trial id="244304"/><TrialEndDateActual/><TrialEndDateCalc>2019-05-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Trial id="224111"/><TrialEndDateActual/><TrialEndDateCalc>2021-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2018-12-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients><ProtocolTitle>Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</ProtocolTitle><Trial id="384080"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>72</Patients><ProtocolTitle>Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis</ProtocolTitle><Trial id="272021"/><TrialEndDateActual/><TrialEndDateCalc>2019-12-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-08-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Trial id="280651"/><TrialEndDateActual/><TrialEndDateCalc>2019-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2017-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44384">ceftriaxone</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>624</Patients><ProtocolTitle>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia</ProtocolTitle><Trial id="377163"/><TrialEndDateActual/><TrialEndDateCalc>2022-07-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2024-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2024-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2020-01-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="25182">valganciclovir</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>624</Patients><ProtocolTitle>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia</ProtocolTitle><Trial id="377163"/><TrialEndDateActual/><TrialEndDateCalc>2022-07-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2024-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2024-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2020-01-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Trial id="259506"/><TrialEndDateActual/><TrialEndDateCalc>2019-04-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Trial id="329251"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-11-03 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-11-03 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Trial id="328802"/><TrialEndDateActual/><TrialEndDateCalc>2012-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2010-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-12-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>630</Patients><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Trial id="244304"/><TrialEndDateActual/><TrialEndDateCalc>2019-05-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>144</Patients><ProtocolTitle>A randomized, multicenter, controlled trial for clofazimine-containing protocol in the treatment of newly diagnosed multidrug-resistant tuberculosis</ProtocolTitle><Trial id="365020"/><TrialEndDateActual/><TrialEndDateCalc>2015-03-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2015-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2015-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2012-12-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>165</Patients><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Trial id="369747"/><TrialEndDateActual/><TrialEndDateCalc>2021-05-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>102</Patients><ProtocolTitle>Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)</ProtocolTitle><Trial id="279727"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-01 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-08-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-04-11 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>165</Patients><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Trial id="369747"/><TrialEndDateActual/><TrialEndDateCalc>2021-05-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Trial id="379769"/><TrialEndDateActual/><TrialEndDateCalc>2021-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-07-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Trial id="334027"/><TrialEndDateActual/><TrialEndDateCalc>2020-08-28 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-04-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1090</Patients><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen</ProtocolTitle><Trial id="247763"/><TrialEndDateActual>2018-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2829">clarithromycin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Trial id="244777"/><TrialEndDateActual/><TrialEndDateCalc>2011-01-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2010-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-10-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Trial id="260814"/><TrialEndDateActual/><TrialEndDateCalc>2018-08-09 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-06-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>108</Patients><ProtocolTitle>Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis</ProtocolTitle><Trial id="371202"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>11</Patients><ProtocolTitle>Doravirine, Rifapentine and Isoniazid Interaction</ProtocolTitle><Trial id="374387"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Trial id="329251"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-11-03 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-11-03 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>7</Patients><ProtocolTitle>Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients</ProtocolTitle><Trial id="182646"/><TrialEndDateActual>2012-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-04-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="81264">interferon gamma follow-on biologic, PHARMACLON LLC</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>90</Patients><ProtocolTitle>Randomized, comparative, controlled, open-label clinical study of efficacy and safety of Ingaron (recombinant human interferon gamma) production of "NPP" FARMAKLON, Russia in the treatment of patients with pulmonary tuberculosis</ProtocolTitle><Trial id="194177"/><TrialEndDateActual/><TrialEndDateCalc>2016-09-14 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2014-07-28 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2014-07-28 00:00:00</TrialEndDateGiven><TrialStartDate>2014-05-26 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Trial id="76946"/><TrialEndDateActual/><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2013-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2013-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>Phase Ic Study of Safety and PK of SQ-109 300 mg Daily</ProtocolTitle><Trial id="77682"/><TrialEndDateActual>2011-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>780</Patients><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Trial id="10681"/><TrialEndDateActual>2010-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-11-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>116</Patients><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Trial id="10863"/><TrialEndDateActual/><TrialEndDateCalc>2008-11-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2011-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>5</Patients><ProtocolTitle>A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV</ProtocolTitle><Trial id="11177"/><TrialEndDateActual>2008-03-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-10-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2008-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2008-03-01 00:00:00</TrialEndDateGiven><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4144">Prevnar</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>302</Patients><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Trial id="65639"/><TrialEndDateActual>2012-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-11-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A phase I study to determine the safety of AERAS-402 in healthy adults, all of whom have been previously vaccinated with the Bacille Calmette-Guerin (BCG) vaccine and a subset of whom have evidence of having been exposed to tuberculosis</ProtocolTitle><Trial id="59617"/><TrialEndDateActual>2009-11-03 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-02-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-11-03 00:00:00</TrialEndDateGiven><TrialStartDate>2008-10-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="76307">delpazolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>64</Patients><ProtocolTitle>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</ProtocolTitle><Trial id="265899"/><TrialEndDateActual/><TrialEndDateCalc>2019-04-01 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-12-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Trial id="90175"/><TrialEndDateActual>2014-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-10-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-05-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="50038">tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Pharmacokinetics of Emtricitabine/Tenofovir + Efavirenz in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Trial id="10945"/><TrialEndDateActual/><TrialEndDateCalc>2011-02-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2009-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2009-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis</ProtocolTitle><Trial id="59043"/><TrialEndDateActual>2010-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3612">meningococcal C/CRM-197 conjugate vaccine, Chiron</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>302</Patients><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Trial id="65639"/><TrialEndDateActual>2012-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-11-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>41</Patients><ProtocolTitle>Linezolid to Treat Extensively-Drug Resistant Tuberculosis</ProtocolTitle><Trial id="23143"/><TrialEndDateActual>2014-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-10-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2008-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>428</Patients><ProtocolTitle>Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis</ProtocolTitle><Trial id="161831"/><TrialEndDateActual/><TrialEndDateCalc>2016-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>144</Patients><ProtocolTitle>Comparative Evaluation of the Effect of Risorine in Patients With Newly Diagnosed Sputum Smear Positive Pulmonary Tuberculosis</ProtocolTitle><Trial id="118547"/><TrialEndDateActual/><TrialEndDateCalc>2013-06-01 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2011-02-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>65</Patients><ProtocolTitle>A Multicenter, Prospective, Randomized, Controlled Trial to Assess  the Efficacy and Safety of Linezolid for the Treatment of Extensively Drug Resistant Tuberculosis in China</ProtocolTitle><Trial id="183541"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44370">clindamycin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>62</Patients><ProtocolTitle>Pharmacokinetics of Antistaphylococcal Antibiotics in Infants</ProtocolTitle><Trial id="98566"/><TrialEndDateActual>2015-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-04-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8050">thalidomide, Celgene</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>50</Patients><ProtocolTitle>Phase II, Placebo-Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections</ProtocolTitle><Trial id="92426"/><TrialEndDateActual>1999-06-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>1992-12-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>1999-06-01 00:00:00</TrialEndDateGiven><TrialStartDate>1990-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>248</Patients><ProtocolTitle>Safety and Immunogenicity of MVA-85A Prime and Bacille Calmette-Guerin Boost Vaccination</ProtocolTitle><Trial id="89833"/><TrialEndDateActual>2015-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>355</Patients><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Trial id="161275"/><TrialEndDateActual>2011-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>155</Patients><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Trial id="40948"/><TrialEndDateActual>2012-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-12-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Trial id="86312"/><TrialEndDateActual>2013-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-09-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A</ProtocolTitle><Trial id="91280"/><TrialEndDateActual>2014-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>88</Patients><ProtocolTitle>TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions</ProtocolTitle><Trial id="74529"/><TrialEndDateActual>2011-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15298">Pentacel</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Trial id="162886"/><TrialEndDateActual>2018-06-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-08-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-06-27 00:00:00</TrialEndDateGiven><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>416</Patients><ProtocolTitle>Study to Evaluate the Safety and Immunogenicity of VPM-1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa</ProtocolTitle><Trial id="224781"/><TrialEndDateActual>2017-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="45998">interferon alfa-2b</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients><ProtocolTitle>Interferon Alpha-2b in the Complex Therapy of Patients With Pulmonary Tuberculosis Concurrent With Broncho-obstructive Syndrome</ProtocolTitle><Trial id="149989"/><TrialEndDateActual>2009-01-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-04-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-01-01 00:00:00</TrialEndDateGiven><TrialStartDate>2007-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients><ProtocolTitle>Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection</ProtocolTitle><Trial id="10687"/><TrialEndDateActual>2008-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen</ProtocolTitle><Trial id="10648"/><TrialEndDateActual/><TrialEndDateCalc>2003-09-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2001-07-02 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>An Open-Label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Doses (md) of TMC-207 Oral Solution (Os) and Isoniazid (JH), TMC-207 Os and Pyrazinamide (JZ), TMC-207 Os and Rifampin (JR) or TMC-207 Os and Isoniazid and Pyrazinamide (JHZ), Compared to the three Principle Drugs of Standard Anti-Tuberculosis Treatment (HRZ) in Treatment-Naive Subjects With Sputum-Smear Positive Pulmonary Tuberculosis</ProtocolTitle><Trial id="131253"/><TrialEndDateActual/><TrialEndDateCalc>2007-10-15 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2005-06-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>47</Patients><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Trial id="11188"/><TrialEndDateActual>2012-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Trial id="150793"/><TrialEndDateActual>2017-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2013-08-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients><ProtocolTitle>Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine</ProtocolTitle><Trial id="10655"/><TrialEndDateActual>2003-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2002-07-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2001-05-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2003-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2000-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Trial id="10646"/><TrialEndDateActual/><TrialEndDateCalc>2002-05-02 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>86</Patients><ProtocolTitle>A study to evaluate the safety and efficacy of moxifloxacin in comparision with cephalexin in patients being treated for uncomplicated skin and soft tissue infections</ProtocolTitle><Trial id="16244"/><TrialEndDateActual/><TrialEndDateCalc>2002-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>217</Patients><ProtocolTitle>A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)</ProtocolTitle><Trial id="152200"/><TrialEndDateActual/><TrialEndDateCalc>2007-03-17 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2006-01-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2006-01-01 00:00:00</TrialEndDateGiven><TrialStartDate>2004-11-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients><ProtocolTitle>A 6-Month Safety, Efficacy and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis</ProtocolTitle><Trial id="133567"/><TrialEndDateActual/><TrialEndDateCalc>2015-11-09 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2013-07-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>68</Patients><ProtocolTitle>A randomized, double-blinded, dose-ranging study to assess the 14-day early bactericidal activity of bedaquiline (TMC-207) in patients with sputum microscopy smear-positive pulmonary tuberculosis</ProtocolTitle><Trial id="139369"/><TrialEndDateActual/><TrialEndDateCalc>2015-06-24 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2013-03-04 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="88505">ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Ethylamine pyrazine Lifestyle Isonicotinic piece IV bioequivalence trials</ProtocolTitle><Trial id="177165"/><TrialEndDateActual/><TrialEndDateCalc>2016-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Trial id="150793"/><TrialEndDateActual>2017-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2013-08-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="84564">ChAdOx1-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>42</Patients><ProtocolTitle>Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults</ProtocolTitle><Trial id="120744"/><TrialEndDateActual>2016-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-11-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>355</Patients><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Trial id="161275"/><TrialEndDateActual>2011-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A Bioavailability Study of Two New Formulations of Bedaquiline on Pediatric Populaion</ProtocolTitle><Trial id="163991"/><TrialEndDateActual/><TrialEndDateCalc>2016-04-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2013-12-14 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>A phase I study to evaluate the safety and immunogenicity of a novel, proprietary prophylactic vaccine MTB72F to induce protection against tuberculosis (TB)</ProtocolTitle><Trial id="9554"/><TrialEndDateActual/><TrialEndDateCalc>2006-06-28 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2004-03-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55173">cadi-05</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1020</Patients><ProtocolTitle>Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients</ProtocolTitle><Trial id="10057"/><TrialEndDateActual>2011-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-07-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2935">didanosine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>642</Patients><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Trial id="201474"/><TrialEndDateActual>2010-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-09-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients><ProtocolTitle>Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects</ProtocolTitle><Trial id="208141"/><TrialEndDateActual>2010-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis</ProtocolTitle><Trial id="242269"/><TrialEndDateActual/><TrialEndDateCalc>2018-09-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-05-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="107803">GamTBvac</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>180</Patients><ProtocolTitle>Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac</ProtocolTitle><Trial id="373676"/><TrialEndDateActual/><TrialEndDateCalc>2021-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-12-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3400</Patients><ProtocolTitle>Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI</ProtocolTitle><Trial id="333384"/><TrialEndDateActual/><TrialEndDateCalc>2021-11-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-07-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1500</Patients><ProtocolTitle>Latent Mycobacterium tuberculosis infection treatment among individuals with a history of prior tuberculosis: a randomized, controlled trial</ProtocolTitle><Trial id="352729"/><TrialEndDateActual/><TrialEndDateCalc>2020-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-09-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Trial id="381674"/><TrialEndDateActual/><TrialEndDateCalc>2021-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2019-08-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Trial id="381674"/><TrialEndDateActual/><TrialEndDateCalc>2021-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2019-08-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2935">didanosine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>592</Patients><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Trial id="8820"/><TrialEndDateActual/><TrialEndDateCalc>2011-11-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>131</Patients><ProtocolTitle>A clinical trial to study the effects of moxifloxacin with regular anti-tuberculosis drugs in Tuberculosis patients</ProtocolTitle><Trial id="255644"/><TrialEndDateActual/><TrialEndDateCalc>2017-12-29 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2015-09-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="105321">superboosted lopinavir + ritonavir (pediatric oral formulation, HIV infection), DNDi</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>96</Patients><ProtocolTitle>Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB</ProtocolTitle><Trial id="220686"/><TrialEndDateActual>2016-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-04-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="61340">S-004992</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase I trial of S-004992 for the potential treatment of drug-resistant tuberculosis</ProtocolTitle><Trial id="334482"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Trial id="244777"/><TrialEndDateActual/><TrialEndDateCalc>2011-01-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2010-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-10-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>Dose-escalation, Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults</ProtocolTitle><Trial id="257534"/><TrialEndDateActual/><TrialEndDateCalc>2018-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Trial id="368916"/><TrialEndDateActual/><TrialEndDateCalc>2022-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2020-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>460</Patients><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Trial id="214156"/><TrialEndDateActual/><TrialEndDateCalc>2018-02-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Trial id="328802"/><TrialEndDateActual/><TrialEndDateCalc>2012-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2010-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-12-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Trial id="334027"/><TrialEndDateActual/><TrialEndDateCalc>2020-08-28 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-04-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>900</Patients><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Trial id="333435"/><TrialEndDateActual/><TrialEndDateCalc>2020-07-10 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-03-12 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-03-12 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis</ProtocolTitle><Trial id="9315"/><TrialEndDateActual>2005-10-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-09-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2005-10-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2005-10-01 00:00:00</TrialEndDateGiven><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="108779">GC-3107</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>750</Patients><ProtocolTitle>A Study of GC-3107(BCG Vaccine) in Healthy Infants</ProtocolTitle><Trial id="380364"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>156</Patients><ProtocolTitle>A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiological Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients</ProtocolTitle><Trial id="8776"/><TrialEndDateActual>1998-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2001-01-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>1998-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>1998-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>2500</Patients><ProtocolTitle>Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349)</ProtocolTitle><Trial id="347338"/><TrialEndDateActual/><TrialEndDateCalc>2020-11-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2018-07-20 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="85970">telacebec</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients><ProtocolTitle>Open, phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic parameters of Q-203 after single and multiple doses in healthy volunteers</ProtocolTitle><Trial id="255234"/><TrialEndDateActual/><TrialEndDateCalc>2018-05-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-11-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>48</Patients><ProtocolTitle>Evaluating the Pharmacokinetics, Safety and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB</ProtocolTitle><Trial id="297373"/><TrialEndDateActual/><TrialEndDateCalc>2020-05-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-05-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-05-01 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>12000</Patients><ProtocolTitle>To Study Effect of Two Vaccines in Preventing Spread of Tuberculosis in Persons Living With New Tuberculosis Patients</ProtocolTitle><Trial id="366261"/><TrialEndDateActual/><TrialEndDateCalc>2021-05-16 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-01-25 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>72</Patients><ProtocolTitle>A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB</ProtocolTitle><Trial id="226801"/><TrialEndDateActual>2010-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>180</Patients><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Trial id="293734"/><TrialEndDateActual/><TrialEndDateCalc>2020-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Trial id="319125"/><TrialEndDateActual/><TrialEndDateCalc>2020-11-18 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-07-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>32</Patients><ProtocolTitle>A phase I, double-blind, randomized, placebo-controlled, safety and immunogenicity study of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection</ProtocolTitle><Trial id="8499"/><TrialEndDateActual>2009-08-11 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-04-11 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-08-11 00:00:00</TrialEndDateGiven><TrialStartDate>2007-12-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2587">azithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1875</Patients><ProtocolTitle>Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis</ProtocolTitle><Trial id="341686"/><TrialEndDateActual/><TrialEndDateCalc>2021-06-16 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-02-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="72148">darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Trial id="260814"/><TrialEndDateActual/><TrialEndDateCalc>2018-08-09 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-06-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>99</Patients><ProtocolTitle>Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates</ProtocolTitle><Trial id="340636"/><TrialEndDateActual/><TrialEndDateCalc>2021-06-02 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-02-11 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>192</Patients><ProtocolTitle>Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT-6-CFP-10</ProtocolTitle><Trial id="219931"/><TrialEndDateActual>2015-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2014-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="107010">TBI-223</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>48</Patients><ProtocolTitle>A Phase 1 Study to Evaluate Safety, Tolerability, and PK of TBI-223 in Healthy Adults</ProtocolTitle><Trial id="362067"/><TrialEndDateActual/><TrialEndDateCalc>2021-05-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-10-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-10-01 00:00:00</TrialEndDateGiven><TrialStartDate>2019-01-16 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="16755">pafuramidine</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>175</Patients><ProtocolTitle>Randomized, double-blind, phase I safety and tolerability study of pafuramidine maleate (DB-289) in healthy subjects</ProtocolTitle><Trial id="17432"/><TrialEndDateActual>2009-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-11-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2008-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2009-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Trial id="375499"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4718">zileuton</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>90</Patients><ProtocolTitle>Optimization of Clinical Treatment Schemes for Multidrug - Resistant Pulmonary Tuberculosis Based on Host - Mediate</ProtocolTitle><Trial id="276708"/><TrialEndDateActual/><TrialEndDateCalc>2019-02-09 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-10-20 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-10-20 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>320</Patients><ProtocolTitle>Evaluation of clofazimine as a part of TB treatment in order to shorten the duration of treatment</ProtocolTitle><Trial id="373668"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-04-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="70581">GSK-3036656</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>80</Patients><ProtocolTitle>An Early Bactericidal Activity, Safety and Tolerability of GSK-3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis</ProtocolTitle><Trial id="343050"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-16 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-09-08 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-09-08 00:00:00</TrialEndDateGiven><TrialStartDate>2019-03-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>220</Patients><ProtocolTitle>Refining MDR-TB Treatment Regimens for Ultra Short Therapy</ProtocolTitle><Trial id="372676"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-12-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-12-01 00:00:00</TrialEndDateGiven><TrialStartDate>2019-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Bioequivalence,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM</ProtocolTitle><Trial id="378146"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>460</Patients><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Trial id="214156"/><TrialEndDateActual/><TrialEndDateCalc>2018-02-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2829">clarithromycin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59386">CC-11050</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>TB Host Directed Therapy</ProtocolTitle><Trial id="279898"/><TrialEndDateActual/><TrialEndDateCalc>2019-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15954">bortezomib</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Evaluating Whole Blood Bactericidal Activity of Bortezomib Against Mycobacterium Tuberculosis in Healthy Volunteers</ProtocolTitle><Trial id="263359"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>Evaluation of SQ-109 Plus PPI in Urea Breath Test-Positive Volunteers</ProtocolTitle><Trial id="72716"/><TrialEndDateActual>2015-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-03-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1354</Patients><ProtocolTitle>Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV</ProtocolTitle><Trial id="187839"/><TrialEndDateActual>2009-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-06-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12132">albendazole</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients><ProtocolTitle>Deworming Against Tuberculosis</ProtocolTitle><Trial id="48176"/><TrialEndDateActual>2013-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-06-23 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients><ProtocolTitle>The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects</ProtocolTitle><Trial id="139433"/><TrialEndDateActual>2013-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-06-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>416</Patients><ProtocolTitle>Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB</ProtocolTitle><Trial id="150332"/><TrialEndDateActual/><TrialEndDateCalc>2006-09-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2004-05-14 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison to BCG in Healthy Volunteers in South Africa</ProtocolTitle><Trial id="65984"/><TrialEndDateActual>2011-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>121</Patients><ProtocolTitle>Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis</ProtocolTitle><Trial id="23035"/><TrialEndDateActual/><TrialEndDateCalc>2012-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2009-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Trial id="210646"/><TrialEndDateActual>2018-02-07 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-02-11 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-02-07 00:00:00</TrialEndDateGiven><TrialStartDate>2014-10-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>47</Patients><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Trial id="11188"/><TrialEndDateActual>2012-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>Pharmacokinetics (PK) and Safety of Two Different Doses of Lopinavir/Ritonavir in HIV/Tuberculosis (TB) Co-Infected Patients Receiving Rifampicin Containing Anti-Tuberculosis Therapy</ProtocolTitle><Trial id="67098"/><TrialEndDateActual>2015-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-02-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients><ProtocolTitle>Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers</ProtocolTitle><Trial id="60906"/><TrialEndDateActual>2010-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>A phase I study to test the safety of AERAS-402 in healthy infants previously vaccinated with the Bacille Calmette-Guerin (BCG) vaccine</ProtocolTitle><Trial id="53622"/><TrialEndDateActual/><TrialEndDateCalc>2011-08-18 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2009-04-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>156</Patients><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Trial id="61991"/><TrialEndDateActual>2011-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-03-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2013-10-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>72</Patients><ProtocolTitle>A phase II, dose escalation study to determine the safety of AERAS-402 in adults who have had active tuberculosis</ProtocolTitle><Trial id="59557"/><TrialEndDateActual/><TrialEndDateCalc>2011-02-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2008-10-17 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Study of AERAS-422 in Healthy Adults</ProtocolTitle><Trial id="76756"/><TrialEndDateActual>2012-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>144</Patients><ProtocolTitle>Clinical Trial for Comparing Safety and Efficacy of Bio-enhanced Rifampicin (Risorine) Capsule in newly diagnosed Pulmonary Tuberculosis in Adult Patients</ProtocolTitle><Trial id="295037"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2017-04-17 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Trial id="63729"/><TrialEndDateActual/><TrialEndDateCalc>2013-01-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>2797</Patients><ProtocolTitle>A Study of MVA-85A in Healthy Infants</ProtocolTitle><Trial id="59405"/><TrialEndDateActual>2012-07-12 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-11-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-07-12 00:00:00</TrialEndDateGiven><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2935">didanosine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>116</Patients><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Trial id="10863"/><TrialEndDateActual/><TrialEndDateCalc>2008-11-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2011-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients><ProtocolTitle>Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz</ProtocolTitle><Trial id="10657"/><TrialEndDateActual>2004-02-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2002-02-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2004-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2004-02-01 00:00:00</TrialEndDateGiven><TrialStartDate>1999-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-Positive Adults</ProtocolTitle><Trial id="19230"/><TrialEndDateActual>2009-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis</ProtocolTitle><Trial id="66735"/><TrialEndDateActual>2011-05-12 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-05-12 00:00:00</TrialEndDateGiven><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients><ProtocolTitle>A multicenter, randomized controlled study to evaluate the clinical efficacy and safety of linezolid in patients with extensively drug resistant tuberculosis</ProtocolTitle><Trial id="173992"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Trial id="90175"/><TrialEndDateActual>2014-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-10-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-05-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Trial id="126486"/><TrialEndDateActual/><TrialEndDateCalc>2014-11-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-09-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="26493">posizolid</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A phase I, double-blind, placebo-controlled, flexible single day ascending dose (SDAD) study to evaluate safety, tolerability and pharmacokinetics (PK) of iv AZD-5847 in healthy subjects</ProtocolTitle><Trial id="82840"/><TrialEndDateActual/><TrialEndDateCalc>2013-08-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2011-09-20 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49162">LL-3858</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A phase I study to evaluate the safety and pharmacokinetics of LL-3858</ProtocolTitle><Trial id="8931"/><TrialEndDateActual>2007-10-07 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-07-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-10-07 00:00:00</TrialEndDateGiven><TrialStartDate>2005-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>182</Patients><ProtocolTitle>Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients</ProtocolTitle><Trial id="63801"/><TrialEndDateActual>2012-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2012-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2012-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12543">ertapenem</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>12</Patients><ProtocolTitle>PK/PD of Ertapenem in Patients with TB</ProtocolTitle><Trial id="98848"/><TrialEndDateActual>2017-07-13 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-05-18 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-07-13 00:00:00</TrialEndDateGiven><TrialStartDate>2017-01-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso</ProtocolTitle><Trial id="161441"/><TrialEndDateActual/><TrialEndDateCalc>2016-04-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2014-11-27 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2014-11-27 00:00:00</TrialEndDateGiven><TrialStartDate>2013-11-28 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Trial id="126486"/><TrialEndDateActual/><TrialEndDateCalc>2014-11-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-09-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>42</Patients><ProtocolTitle>Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults</ProtocolTitle><Trial id="120744"/><TrialEndDateActual>2016-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-11-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z)</ProtocolTitle><Trial id="92275"/><TrialEndDateActual>2013-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12813">Rotarix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Trial id="162886"/><TrialEndDateActual>2018-06-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-08-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-06-27 00:00:00</TrialEndDateGiven><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>355</Patients><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Trial id="161275"/><TrialEndDateActual>2011-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8255">nelfinavir</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Trial id="10646"/><TrialEndDateActual/><TrialEndDateCalc>2002-05-02 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>RIFART</ProtocolTitle><Trial id="131240"/><TrialEndDateActual>2011-04-19 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-05-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-19 00:00:00</TrialEndDateGiven><TrialStartDate>2005-03-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients><ProtocolTitle>Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects</ProtocolTitle><Trial id="120522"/><TrialEndDateActual>2007-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>347</Patients><ProtocolTitle>A phase III study to evaluate the safety and efficacy of SRL-172 for the prevention of tuberculosis</ProtocolTitle><Trial id="20002"/><TrialEndDateActual>1997-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2000-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>1997-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>1997-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients><ProtocolTitle>Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)</ProtocolTitle><Trial id="48035"/><TrialEndDateActual>2010-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>15</Patients><ProtocolTitle>A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects</ProtocolTitle><Trial id="25327"/><TrialEndDateActual>2008-10-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-11-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-10-01 00:00:00</TrialEndDateGiven><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>42</Patients><ProtocolTitle>Efficacy Safety Study Comparing two Doses of NVP After Initiating Rifampin-Containing TB Therapy</ProtocolTitle><Trial id="10946"/><TrialEndDateActual>2009-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-01-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>207</Patients><ProtocolTitle>Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)</ProtocolTitle><Trial id="83489"/><TrialEndDateActual>2013-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-07-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Trial id="10646"/><TrialEndDateActual/><TrialEndDateCalc>2002-05-02 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis</ProtocolTitle><Trial id="132087"/><TrialEndDateActual>2017-12-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-10-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-12-28 00:00:00</TrialEndDateGiven><TrialStartDate>2013-06-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>High-Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis</ProtocolTitle><Trial id="63261"/><TrialEndDateActual>2010-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5321">indinavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><Trial id="100728"/><TrialEndDateActual/><TrialEndDateCalc>2014-03-24 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-01-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Trial id="10646"/><TrialEndDateActual/><TrialEndDateCalc>2002-05-02 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A open-labeled study to assess the efficacy of levofloxacin in healthy volunteers</ProtocolTitle><Trial id="113606"/><TrialEndDateActual/><TrialEndDateCalc>2014-05-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Trial id="63729"/><TrialEndDateActual/><TrialEndDateCalc>2013-01-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="81037">Wei Ka</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>10000</Patients><ProtocolTitle>Phase III Clinical Study of Efficacy and Safety of Vaccae to Prevent Tuberculosis</ProtocolTitle><Trial id="160177"/><TrialEndDateActual>2017-11-26 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-11-26 00:00:00</TrialEndDateGiven><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Trial id="162886"/><TrialEndDateActual>2018-06-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-08-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-06-27 00:00:00</TrialEndDateGiven><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="46927">doxycycline hyclate</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana</ProtocolTitle><Trial id="214864"/><TrialEndDateActual>2017-03-15 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-01-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-03-15 00:00:00</TrialEndDateGiven><TrialStartDate>2014-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1107</Patients><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Trial id="195741"/><TrialEndDateActual>2015-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-06-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients><ProtocolTitle>Treatment of Latent Tuberculosis in Socially Marginalised Citizens</ProtocolTitle><Trial id="310930"/><TrialEndDateActual/><TrialEndDateCalc>2020-02-16 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2026-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2026-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-10-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81363">AEC/BC02</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>135</Patients><ProtocolTitle>A Phase I Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried</ProtocolTitle><Trial id="285854"/><TrialEndDateActual/><TrialEndDateCalc>2020-08-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-08-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-04-16 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>92</Patients><ProtocolTitle>Randomized, Open-label, Comparative Study to Evaluate the Rifapentine in the Treatment of Patients Newly Diagnosed with Pulmonary Tuberculosis Negative and Smear-with Preserved Sensitivity of Mycobacteria</ProtocolTitle><Trial id="168261"/><TrialEndDateActual/><TrialEndDateCalc>2014-01-16 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2012-09-06 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2012-09-06 00:00:00</TrialEndDateGiven><TrialStartDate>2011-09-27 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="87251">Perchlozone</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Perchlozone in the treatment of patients with pulmonary tuberculosis with MDR-TB, including HIV</ProtocolTitle><Trial id="291547"/><TrialEndDateActual/><TrialEndDateCalc>2019-06-30 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2017-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2017-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-03-10 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients><ProtocolTitle>Safety, Tolerability and Immunogenicity of the Vaccine Candidates ID-93 + AP10-602 and ID-93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects</ProtocolTitle><Trial id="235751"/><TrialEndDateActual>2017-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-02-10 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-10-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>153</Patients><ProtocolTitle>Study of Daily Rifapentine for Pulmonary Tuberculosis</ProtocolTitle><Trial id="39550"/><TrialEndDateActual>2014-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>14</Patients><ProtocolTitle>Study to assess the bioequivalence of two oral formulations of levofloxacin tablets: FLEVOX (SERRAL, SA de CV), versus TAVANIC (Sanofi-Aventis of Mexico, SA de CV), after administration of a single dose- 500 mg to healthy adult subjects of both genders, in the fasting state</ProtocolTitle><Trial id="227604"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>262</Patients><ProtocolTitle>NexGen EBA Radiological and Immunological Biomarkers of Sterilizing Drug Activity in Tuberculosis</ProtocolTitle><Trial id="222933"/><TrialEndDateActual>2017-11-14 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-06-16 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-11-14 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis</ProtocolTitle><Trial id="242269"/><TrialEndDateActual/><TrialEndDateCalc>2018-09-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-05-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1556</Patients><ProtocolTitle>Tuberculosis child multidrug-resistant preventive therapy</ProtocolTitle><Trial id="259562"/><TrialEndDateActual/><TrialEndDateCalc>2018-04-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A prospective, single-centre pharmacokinetic study to develop population pharmacokinetic models for second-line drugs in patients with multi-drug-resistant tuberculosis, evaluate the recommended dosage regimens and, if necessary, suggest new dosage regimens</ProtocolTitle><Trial id="304264"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>107</Patients><ProtocolTitle>Phase IIa Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers</ProtocolTitle><Trial id="366580"/><TrialEndDateActual/><TrialEndDateCalc>2020-09-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2018-05-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients><ProtocolTitle>Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin</ProtocolTitle><Trial id="254949"/><TrialEndDateActual>2014-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-06-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients><ProtocolTitle>Open-label, randomized, crossover study of the comparative pharmacokinetics and bioequivalence of drugs moxifloxacin film-coated tablets 400 mg (JSC "Synthesis", Russia) and Avelox tablets, film-coated 400 mg (Bayer Pharma AG, Germany) in healthy volunteers on an empty stomach</ProtocolTitle><Trial id="255583"/><TrialEndDateActual/><TrialEndDateCalc>2017-09-05 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2017-10-16 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2017-10-16 00:00:00</TrialEndDateGiven><TrialStartDate>2016-03-04 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="107523">TBA-7371</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>74</Patients><ProtocolTitle>A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371</ProtocolTitle><Trial id="303756"/><TrialEndDateActual>2018-07-08 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-12-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-07-08 00:00:00</TrialEndDateGiven><TrialStartDate>2017-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Trial id="368916"/><TrialEndDateActual/><TrialEndDateCalc>2022-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2020-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3000</Patients><ProtocolTitle>Novel Triple-Dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More</ProtocolTitle><Trial id="372353"/><TrialEndDateActual/><TrialEndDateCalc>2022-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-10-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-10-01 00:00:00</TrialEndDateGiven><TrialStartDate>2019-09-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients><ProtocolTitle>Brief Bactericidal Activity of Anti-Tuberculosis Drugs</ProtocolTitle><Trial id="210083"/><TrialEndDateActual/><TrialEndDateCalc>2018-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>109</Patients><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Trial id="219499"/><TrialEndDateActual/><TrialEndDateCalc>2017-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-10-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>6</Patients><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Trial id="222400"/><TrialEndDateActual>2018-11-08 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-05-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-11-08 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>155</Patients><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Trial id="40948"/><TrialEndDateActual>2012-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-12-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients><ProtocolTitle>A phase IIb/III, international, multicenter, prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of chemotherapy regimens, including drug SQ-109 in patients with pulmonary multidrug-resistant mycobacterium tuberculosis</ProtocolTitle><Trial id="168785"/><TrialEndDateActual>2016-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-10-17 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2012-06-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>160</Patients><ProtocolTitle>Anti-bacterial Activity, Safety, and Tolerability of TMC-207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)</ProtocolTitle><Trial id="9302"/><TrialEndDateActual>2012-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients><ProtocolTitle>A study to investigate the safety and efficacy of bedaquiline and linezolid chemotherapy for extensively drug-resistant pulmonary tuberculosis within 6 months period</ProtocolTitle><Trial id="280303"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4155">pravastatin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Statin Adjunctive Therapy for TB: A Phase IIb Dose-finding Study of Pravastatin in Adults With Tuberculosis</ProtocolTitle><Trial id="374083"/><TrialEndDateActual/><TrialEndDateCalc>2021-10-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-06-16 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-06-16 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-15 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="6050">metformin hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients><ProtocolTitle>Effect of metformin in treatment of non-diabetic pulmonary tuberculosis patients</ProtocolTitle><Trial id="372893"/><TrialEndDateActual/><TrialEndDateCalc>2021-06-26 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-03-07 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25023">golotimod</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients><ProtocolTitle>A Phase II Trial To Study SCV-07 in Tuberculosis (TB) Patients Receiving Standard Anti-TB Chemotherapy</ProtocolTitle><Trial id="9345"/><TrialEndDateActual/><TrialEndDateCalc>2005-01-17 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2002-09-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="104087">FS-1</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>480</Patients><ProtocolTitle>FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis</ProtocolTitle><Trial id="246553"/><TrialEndDateActual/><TrialEndDateCalc>2016-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>2</Patients><ProtocolTitle>MVA-85A Aerosol Versus Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M tb) Infection</ProtocolTitle><Trial id="238674"/><TrialEndDateActual>2018-10-04 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-10-04 00:00:00</TrialEndDateGiven><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Trial id="379769"/><TrialEndDateActual/><TrialEndDateCalc>2021-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-07-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients><ProtocolTitle>A study to investigate the safety and efficacy of bedaquiline and linezolid chemotherapy for extensively drug-resistant pulmonary tuberculosis within 6 months period</ProtocolTitle><Trial id="280303"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="52139">ofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12135">celecoxib</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients><ProtocolTitle>Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers</ProtocolTitle><Trial id="245694"/><TrialEndDateActual>2016-02-29 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="98373">TB/FLU-04L</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>80</Patients><ProtocolTitle>A randomized, double-blind, placebo-controlled, phase II clinical trial of TB/FLU-04L TB vaccine in adult volunteers with signs of latent tuberculosis infection</ProtocolTitle><Trial id="301908"/><TrialEndDateActual/><TrialEndDateCalc>2019-09-25 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-05-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-05-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-05 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>62</Patients><ProtocolTitle>Phase I clinical trial of single-dose of PA-824</ProtocolTitle><Trial id="362102"/><TrialEndDateActual/><TrialEndDateCalc>2020-07-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2018-03-14 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>48</Patients><ProtocolTitle>Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function</ProtocolTitle><Trial id="375406"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-28 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-10-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-10-01 00:00:00</TrialEndDateGiven><TrialStartDate>2019-05-09 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis</ProtocolTitle><Trial id="8842"/><TrialEndDateActual>2007-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>165</Patients><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Trial id="369747"/><TrialEndDateActual/><TrialEndDateCalc>2021-05-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>530</Patients><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Trial id="228190"/><TrialEndDateActual/><TrialEndDateCalc>2018-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44309">ranitidine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Trial id="360104"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-08-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-08-01 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-02 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>380</Patients><ProtocolTitle>Clofazimine treatment of multidrug-resistant tuberculosis (MDRTB)</ProtocolTitle><Trial id="284370"/><TrialEndDateActual>2016-12-23 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-06-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-12-23 00:00:00</TrialEndDateGiven><TrialStartDate>2016-03-01 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>2000</Patients><ProtocolTitle>Phase II/III Study To Check The Efficacy And Safety Of Recombinant BCG Vaccine In TB Patients In India</ProtocolTitle><Trial id="292836"/><TrialEndDateActual/><TrialEndDateCalc>2019-07-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2017-04-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Trial id="381674"/><TrialEndDateActual/><TrialEndDateCalc>2021-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2019-08-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>To observe if administration of drug namely linezolid along with standard four drug regimen in intensive(initial) phase of Tubercular meningitis will help reduce death and disability among patients when compared to standard four drug antitubercular drug therapy alone</ProtocolTitle><Trial id="383209"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-23 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-06-07 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Recombinant Mycobacterium tuberculosis allergen ESAT6-CFP10 for 18 to 65 years old healthy people: randomized, blinded, parallel-group phase III clinical trial</ProtocolTitle><Trial id="252783"/><TrialEndDateActual/><TrialEndDateCalc>2018-06-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-05-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-02-17 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="48140">doxycycline (once-daily, oral controlled release), CollaGenex</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana</ProtocolTitle><Trial id="214864"/><TrialEndDateActual>2017-03-15 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-01-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-03-15 00:00:00</TrialEndDateGiven><TrialStartDate>2014-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>155</Patients><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Trial id="40948"/><TrialEndDateActual>2012-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-12-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>96</Patients><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen for Children</ProtocolTitle><Trial id="285889"/><TrialEndDateActual>2018-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>84</Patients><ProtocolTitle>Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents</ProtocolTitle><Trial id="223463"/><TrialEndDateActual>2016-12-09 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-09-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-12-09 00:00:00</TrialEndDateGiven><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients><ProtocolTitle>A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers</ProtocolTitle><Trial id="303292"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-10-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>419</Patients><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Trial id="280225"/><TrialEndDateActual>2018-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-04-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Trial id="329251"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-25 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-11-03 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-11-03 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74480">doravirine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>11</Patients><ProtocolTitle>Doravirine, Rifapentine and Isoniazid Interaction</ProtocolTitle><Trial id="374387"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>302</Patients><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Trial id="65639"/><TrialEndDateActual>2012-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-11-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Phase IIa ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion</ProtocolTitle><Trial id="231367"/><TrialEndDateActual>2017-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="26574">lamivudine + abacavir + zidovudine, GSK</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients><ProtocolTitle>Tuberculosis and HIV Immune Reconstitution Syndrome Trial (THIRST)</ProtocolTitle><Trial id="47398"/><TrialEndDateActual>2007-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-09-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2007-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2007-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2004-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>33</Patients><ProtocolTitle>TMC-207 +/- Rifabutin/Rifampin</ProtocolTitle><Trial id="76765"/><TrialEndDateActual>2012-05-23 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-02-09 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-05-23 00:00:00</TrialEndDateGiven><TrialStartDate>2011-10-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>A phase I study of a new tuberculosis (TB) vaccine, MVA-85A, in healthy volunteers with HIV</ProtocolTitle><Trial id="23059"/><TrialEndDateActual>2011-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46927">doxycycline hyclate</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>Doxycycline in Human Pulmonary Tuberculosis</ProtocolTitle><Trial id="261320"/><TrialEndDateActual>2017-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>145</Patients><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Trial id="10947"/><TrialEndDateActual>2010-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>12</Patients><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers</ProtocolTitle><Trial id="10872"/><TrialEndDateActual>2005-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2005-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2005-07-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2005-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2003-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>16</Patients><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG</ProtocolTitle><Trial id="10874"/><TrialEndDateActual>2006-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2005-09-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2005-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2006-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2003-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Bioavailability</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A phase II trial of rifapentine in comparision with rifampicin to evaluate bioavailability in treatment of patients with pulmonary tuberculosis</ProtocolTitle><Trial id="15342"/><TrialEndDateActual/><TrialEndDateCalc>1990-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1987-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>233</Patients><ProtocolTitle>To Evaluate the Safety, Tolerability, and Efficacy of TMC-207 as Part of an Individualized Multi-Drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-Positive Pulmonary MDR-TB</ProtocolTitle><Trial id="56974"/><TrialEndDateActual>2013-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>12</Patients><ProtocolTitle>TCell Turnover Following Vaccination With MVA-85A</ProtocolTitle><Trial id="11182"/><TrialEndDateActual>2010-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-02-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>47</Patients><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Trial id="11188"/><TrialEndDateActual>2012-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Trial id="126486"/><TrialEndDateActual/><TrialEndDateCalc>2014-11-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-09-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>487</Patients><ProtocolTitle>Study of AERAS-402 in Healthy Infants</ProtocolTitle><Trial id="70158"/><TrialEndDateActual>2014-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients><ProtocolTitle>Brief Bactericidal Activity of Anti-Tuberculosis Drugs</ProtocolTitle><Trial id="210083"/><TrialEndDateActual/><TrialEndDateCalc>2018-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients><ProtocolTitle>Efficacy Against TB Disease, Safety, and Immunogenicity of MVA-85A/AERAS-485 in HIV-Infected Adults</ProtocolTitle><Trial id="67841"/><TrialEndDateActual>2014-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-11-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients><ProtocolTitle>The Treatment of Tuberculosis in HIV-Infected Patients</ProtocolTitle><Trial id="10643"/><TrialEndDateActual>1997-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven>1997-07-31 00:00:00</TrialEndDateGiven><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>53</Patients><ProtocolTitle>Population Pharmacokinetics of Nevirapine in Combination With Rifampicin-Based Short Course Chemotherapy in HIV- and Tuberculosis-Infected South African Patients</ProtocolTitle><Trial id="149504"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>33</Patients><ProtocolTitle>TMC-207 +/- Rifabutin/Rifampin</ProtocolTitle><Trial id="76765"/><TrialEndDateActual>2012-05-23 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-02-09 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-05-23 00:00:00</TrialEndDateGiven><TrialStartDate>2011-10-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55521">golotimod (oral), SciClone/Verta</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Phase I Trial to Compare Oral Formulation of Golotimod Versus that of Subcutaneous and Sublingual Formulations of Golotimod in Healthy Volunteers for the treatment of Tuberculosis (TB)</ProtocolTitle><Trial id="8932"/><TrialEndDateActual/><TrialEndDateCalc>2008-09-13 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2006-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2006-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-05-25 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>511</Patients><ProtocolTitle>Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug Resistant Tuberculosis</ProtocolTitle><Trial id="80386"/><TrialEndDateActual>2016-07-04 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-07-04 00:00:00</TrialEndDateGiven><TrialStartDate>2011-09-02 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3517">losartan</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Trial id="122291"/><TrialEndDateActual>2011-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients><ProtocolTitle>Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis</ProtocolTitle><Trial id="158535"/><TrialEndDateActual>2013-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>540</Patients><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Trial id="145651"/><TrialEndDateActual>2010-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>64</Patients><ProtocolTitle>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</ProtocolTitle><Trial id="265899"/><TrialEndDateActual/><TrialEndDateCalc>2019-04-01 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-12-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>570</Patients><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Trial id="10948"/><TrialEndDateActual>2011-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-03-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2011-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>337</Patients><ProtocolTitle>A dose-finding, multicenter, open-label study to investigate the efficacy of SRL-172 vaccine in the treatment of multidrug-resistant pulmonary tuberculosis</ProtocolTitle><Trial id="110339"/><TrialEndDateActual/><TrialEndDateCalc>2003-05-01 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2001-01-09 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>135</Patients><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Trial id="114300"/><TrialEndDateActual>2013-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-09-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>109</Patients><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Trial id="219499"/><TrialEndDateActual/><TrialEndDateCalc>2017-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-10-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Trial id="162886"/><TrialEndDateActual>2018-06-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-08-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-06-27 00:00:00</TrialEndDateGiven><TrialStartDate>2014-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>65</Patients><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Trial id="71107"/><TrialEndDateActual>2011-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-02-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>215</Patients><ProtocolTitle>Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen</ProtocolTitle><Trial id="10653"/><TrialEndDateActual>2004-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2001-05-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2003-02-28 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2004-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>1999-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8050">thalidomide, Celgene</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients><ProtocolTitle>Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role</ProtocolTitle><Trial id="150307"/><TrialEndDateActual>2000-08-01 00:00:00</TrialEndDateActual><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven>2000-08-01 00:00:00</TrialEndDateGiven><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>355</Patients><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Trial id="161275"/><TrialEndDateActual>2011-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>An Evaluation of the Pharmacological Interaction of Lopinavir/ritonavir and Rifampin</ProtocolTitle><Trial id="171009"/><TrialEndDateActual>2012-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-02-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Combination of Two Drugs in Tuberculosis Treatment</ProtocolTitle><Trial id="224091"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Trial id="63729"/><TrialEndDateActual/><TrialEndDateCalc>2013-01-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients><ProtocolTitle>Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naive Healthy Adults in the US</ProtocolTitle><Trial id="227341"/><TrialEndDateActual>2015-10-13 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-09-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-10-13 00:00:00</TrialEndDateGiven><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10</ProtocolTitle><Trial id="163196"/><TrialEndDateActual>2013-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients><ProtocolTitle>An open-label, comparative, multicenter trial to evaluate long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis</ProtocolTitle><Trial id="113726"/><TrialEndDateActual/><TrialEndDateCalc>2005-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2003-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="6306">aldesleukin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>110</Patients><ProtocolTitle>A randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of IL-2 for the treatment of patients with pulmonary tuberculosis</ProtocolTitle><Trial id="73321"/><TrialEndDateActual/><TrialEndDateCalc>2005-03-12 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2002-11-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1107</Patients><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Trial id="195741"/><TrialEndDateActual>2015-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-06-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>116</Patients><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Trial id="10863"/><TrialEndDateActual/><TrialEndDateCalc>2008-11-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2011-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>181</Patients><ProtocolTitle>Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) in Healthy Adults</ProtocolTitle><Trial id="11263"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="6748">Recombivax HB</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>185</Patients><ProtocolTitle>A Trial Investigating the Influence of BCG and Hepatitis B Immunization at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study</ProtocolTitle><Trial id="229498"/><TrialEndDateActual>2016-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-08-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Pharmacokinetics of rifapentine and isoniazid and NAT2 and SLCO1B1 polymorphisms in pediatric Thai patients with latent tuberculosis infection</ProtocolTitle><Trial id="379095"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>566</Patients><ProtocolTitle>Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention</ProtocolTitle><Trial id="228560"/><TrialEndDateActual/><TrialEndDateCalc>2017-07-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16696">lamivudine + zidovudine, GlaxoSmithKline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>135</Patients><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Trial id="114300"/><TrialEndDateActual>2013-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-09-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>21</Patients><ProtocolTitle>Bioequivalence Study Comparing Rifampicin In A Fixed-dose Combination (Rifampicin + Isoniazid, Myrin 2) And The Reference Drug (Rifampicin, Rimactane)</ProtocolTitle><Trial id="164313"/><TrialEndDateActual>2011-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2011-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients><ProtocolTitle>Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid</ProtocolTitle><Trial id="265766"/><TrialEndDateActual/><TrialEndDateCalc>2019-03-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-02-28 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>72</Patients><ProtocolTitle>EMaBS TB Vaccine Study</ProtocolTitle><Trial id="354327"/><TrialEndDateActual/><TrialEndDateCalc>2021-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-12-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>2500</Patients><ProtocolTitle>Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals</ProtocolTitle><Trial id="364544"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-03-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="90085">macozinone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>192</Patients><ProtocolTitle>International, multicenter, double-blind, placebo-controlled, randomized trial to evaluate the efficacy, safety and pharmacokinetics of PBTZ-169 when used in combination therapy in patients with tuberculosis of respiratory organs with bacterial excretion and drug resistance</ProtocolTitle><Trial id="316145"/><TrialEndDateActual/><TrialEndDateCalc>2019-12-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-03-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-03-01 00:00:00</TrialEndDateGiven><TrialStartDate>2017-08-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Trial id="11187"/><TrialEndDateActual>2010-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw</ProtocolTitle><Trial id="226826"/><TrialEndDateActual/><TrialEndDateCalc>2017-09-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>592</Patients><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Trial id="8820"/><TrialEndDateActual/><TrialEndDateCalc>2011-11-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44406">imipenem + cilastatin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>69</Patients><ProtocolTitle>A study to evaluate the efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in patients with newly diagnosed pulmonary tuberculosis</ProtocolTitle><Trial id="280029"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Trial id="259506"/><TrialEndDateActual/><TrialEndDateCalc>2019-04-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Trial id="328802"/><TrialEndDateActual/><TrialEndDateCalc>2012-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2010-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-12-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects</ProtocolTitle><Trial id="227410"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-01 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-11 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-11 00:00:00</TrialEndDateGiven><TrialStartDate>2017-12-11 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>A study to evaluate the pharmacokinetics of levofloxacin in children who received levofloxacin-based tuberculosis preventive therapy</ProtocolTitle><Trial id="380303"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Trial id="334027"/><TrialEndDateActual/><TrialEndDateCalc>2020-08-28 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-04-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3616">meropenem</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A study on the uptake, distribution and excretion of bedaquiline, a medicine against tuberculosis, in people with type 2 diabetes</ProtocolTitle><Trial id="331962"/><TrialEndDateActual/><TrialEndDateCalc>2019-12-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Trial id="375499"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="95442">ESAT-6CFP10</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1044</Patients><ProtocolTitle>Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65</ProtocolTitle><Trial id="224675"/><TrialEndDateActual>2015-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>50</Patients><ProtocolTitle>Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-Negative Adults</ProtocolTitle><Trial id="9540"/><TrialEndDateActual>2005-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-11-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2005-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44309">ranitidine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Trial id="360104"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-08-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-08-01 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-02 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3412">ivermectin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients><ProtocolTitle>Tuberculosis - Learning the Impact of Nutrition</ProtocolTitle><Trial id="347635"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Pharmacokinetic Study of Linezolid for TB Meningitis</ProtocolTitle><Trial id="340851"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>900</Patients><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Trial id="333435"/><TrialEndDateActual/><TrialEndDateCalc>2020-07-10 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-03-12 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-03-12 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Trial id="369109"/><TrialEndDateActual/><TrialEndDateCalc>2021-06-27 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-03-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="90231">DAR-901</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients><ProtocolTitle>DAR-901 TB Booster Vaccine to Prevent TB in Adolescents</ProtocolTitle><Trial id="256110"/><TrialEndDateActual/><TrialEndDateCalc>2018-07-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44313">simvastatin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>321</Patients><ProtocolTitle>Simvastatin and sputum conversion in pulmonary tuberculosis: a double-blinded, randomized, controlled trial</ProtocolTitle><Trial id="330023"/><TrialEndDateActual/><TrialEndDateCalc>2020-07-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2018-04-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55173">cadi-05</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients><ProtocolTitle>Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients</ProtocolTitle><Trial id="10866"/><TrialEndDateActual>2012-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12013">once-daily naproxen (oral controlled release, pain), Alvogen</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial</ProtocolTitle><Trial id="199754"/><TrialEndDateActual/><TrialEndDateCalc>2016-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients><ProtocolTitle>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</ProtocolTitle><Trial id="68204"/><TrialEndDateActual>2011-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3000</Patients><ProtocolTitle>Brief Rifapentine-Isoniazid Evaluation for TB Prevention</ProtocolTitle><Trial id="79741"/><TrialEndDateActual>2017-11-14 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-09-12 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-11-14 00:00:00</TrialEndDateGiven><TrialStartDate>2012-05-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Bioequivalence,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>410</Patients><ProtocolTitle>Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment TBTC/UITB Study 28</ProtocolTitle><Trial id="155451"/><TrialEndDateActual/><TrialEndDateCalc>2008-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2006-05-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>155</Patients><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Trial id="40948"/><TrialEndDateActual>2012-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-12-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7310">ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients><ProtocolTitle>A prospective, open-label, pilot study to evaluate the pharmacokinetics (PK)/safety/efficacy of an adjusted dose of indinavir/ritonavir (IDV/r) 600/100 mg plus two nucleoside reverse transcriptase inhibitors (NRTIs) in HIV/TB-coinfected Thais receiving rifampicin-based anti-TB treatment</ProtocolTitle><Trial id="100728"/><TrialEndDateActual/><TrialEndDateCalc>2014-03-24 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-01-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Trial id="11187"/><TrialEndDateActual>2010-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>12</Patients><ProtocolTitle>Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB</ProtocolTitle><Trial id="10941"/><TrialEndDateActual>2007-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>19</Patients><ProtocolTitle>Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis</ProtocolTitle><Trial id="192117"/><TrialEndDateActual>2017-12-29 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-04-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-12-29 00:00:00</TrialEndDateGiven><TrialStartDate>2008-12-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12014">VP-101</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>288</Patients><ProtocolTitle>Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)</ProtocolTitle><Trial id="142323"/><TrialEndDateActual>2014-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14493">tenofovir disoproxil fumarate</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>780</Patients><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Trial id="10681"/><TrialEndDateActual>2010-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-11-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>19</Patients><ProtocolTitle>Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis</ProtocolTitle><Trial id="150522"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Trial id="10869"/><TrialEndDateActual>2007-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-06-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>58</Patients><ProtocolTitle>Improving Retreatment Success</ProtocolTitle><Trial id="182040"/><TrialEndDateActual>2017-07-17 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-07-17 00:00:00</TrialEndDateGiven><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>9</Patients><ProtocolTitle>Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin</ProtocolTitle><Trial id="93494"/><TrialEndDateActual>2018-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-05-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients><ProtocolTitle>The Effect of Intermittent Rifampicin on Raltegravir</ProtocolTitle><Trial id="80394"/><TrialEndDateActual>2013-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62397">AERAS-407 rBCG</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Study of AERAS-422 in Healthy Adults</ProtocolTitle><Trial id="76756"/><TrialEndDateActual>2012-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44303">midazolam hydrochloride</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>13</Patients><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Trial id="122291"/><TrialEndDateActual>2011-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Trial id="90175"/><TrialEndDateActual>2014-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-10-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-05-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="26493">posizolid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>Phase IIa EBA Trial of AZD-5847</ProtocolTitle><Trial id="84246"/><TrialEndDateActual>2013-12-24 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-03-27 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-12-24 00:00:00</TrialEndDateGiven><TrialStartDate>2012-12-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="54488">raltegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>108</Patients><ProtocolTitle>Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-containing Antiretroviral Therapy (ART) Regimen in Infants and Children Infected With HIV and TB</ProtocolTitle><Trial id="102102"/><TrialEndDateActual/><TrialEndDateCalc>2016-10-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2014-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1931</Patients><ProtocolTitle>Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis</ProtocolTitle><Trial id="49258"/><TrialEndDateActual>2014-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-04-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2008-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients><ProtocolTitle>Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine</ProtocolTitle><Trial id="10943"/><TrialEndDateActual>2008-08-24 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-08-24 00:00:00</TrialEndDateGiven><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of TMC-207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis</ProtocolTitle><Trial id="87533"/><TrialEndDateActual/><TrialEndDateCalc>2016-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44316">zidovudine</Drug><Endpoint>Safety,Efficacy,Bioavailability</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Trial id="136052"/><TrialEndDateActual/><TrialEndDateCalc>2008-08-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2006-05-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>207</Patients><ProtocolTitle>Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)</ProtocolTitle><Trial id="83489"/><TrialEndDateActual>2013-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-07-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="31010">SQ-109</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>365</Patients><ProtocolTitle>Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design</ProtocolTitle><Trial id="109063"/><TrialEndDateActual>2015-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>780</Patients><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Trial id="10681"/><TrialEndDateActual>2010-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-11-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A</ProtocolTitle><Trial id="91280"/><TrialEndDateActual>2014-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>817</Patients><ProtocolTitle>A randomized, double-blind, placebo-controlled trial to investigate the effect of intensified treatment with high dose rifampicin and levofloxacin for adult patients with tuberculous meningitis</ProtocolTitle><Trial id="75317"/><TrialEndDateActual>2015-03-15 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-08-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-03-15 00:00:00</TrialEndDateGiven><TrialStartDate>2011-04-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13624">BCG vaccine, Organon</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients><ProtocolTitle>Challenge Model for Assessment of Human TB Immunity</ProtocolTitle><Trial id="149358"/><TrialEndDateActual/><TrialEndDateCalc>2016-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB</ProtocolTitle><Trial id="10656"/><TrialEndDateActual>2005-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2002-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2002-02-28 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2005-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2000-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="28379">Glutoxim</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>Glutoxim in the Surgical Treatment of Patients With Pulmonary Tuberculosis</ProtocolTitle><Trial id="149224"/><TrialEndDateActual>2007-01-01 00:00:00</TrialEndDateActual><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven>2007-01-01 00:00:00</TrialEndDateGiven><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy,Bioavailability</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Trial id="136052"/><TrialEndDateActual/><TrialEndDateCalc>2008-08-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2006-05-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>7731</Patients><ProtocolTitle>A 3 Months of Weekly Rifapentine and Isoniazid for M Tuberculosis Infection</ProtocolTitle><Trial id="10659"/><TrialEndDateActual>2013-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2003-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2001-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients><ProtocolTitle>TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer</ProtocolTitle><Trial id="42128"/><TrialEndDateActual>2009-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="39069">simeprevir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>21</Patients><ProtocolTitle>TMC-435350-TiDP16-C105:  Phase I, Three-Way Crossover, Drug-Drug Interaction Between TMC-435350 and Rifampin After Multiple Dosing</ProtocolTitle><Trial id="25800"/><TrialEndDateActual>2008-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>990</Patients><ProtocolTitle>A Randomized, Placebo-Controlled, Partially-Blinded, Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents</ProtocolTitle><Trial id="176219"/><TrialEndDateActual>2017-10-06 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-10-06 00:00:00</TrialEndDateGiven><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Trial id="11187"/><TrialEndDateActual>2010-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3610">meloxicam</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial</ProtocolTitle><Trial id="172626"/><TrialEndDateActual/><TrialEndDateCalc>2016-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2015-03-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2015-03-01 00:00:00</TrialEndDateGiven><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="87251">Perchlozone</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>340</Patients><ProtocolTitle>Multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of the drug Perhlozone in the treatment of patients with pulmonary MDR MBT, including the presence of HIV infection</ProtocolTitle><Trial id="183939"/><TrialEndDateActual/><TrialEndDateCalc>2016-07-28 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-05-03 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-05-03 00:00:00</TrialEndDateGiven><TrialStartDate>2014-04-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9354">picroliv</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>260</Patients><ProtocolTitle>Evaluation of Hepatoprotective Effect of Picroliv in Patients Receiving Multi Drug Therapy of Tuberculosis</ProtocolTitle><Trial id="127798"/><TrialEndDateActual>2010-05-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-06-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-05-01 00:00:00</TrialEndDateGiven><TrialStartDate>2005-03-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>17</Patients><ProtocolTitle>A Non-randomized, Uncontrolled, Single-group Study of Short-course Isoniazid plus Rifapentine Directly Observed Therapy for Latent Tuberculosis in Solid-organ Transplant Candidates</ProtocolTitle><Trial id="159244"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="98013">isoniazid + rifampicin + pyrazinamide + ethambutol</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients><ProtocolTitle>Using electronic monitors and a smartphone app to improve treatment adherence of new pulmonary tuberculosis patients in Tibet, China</ProtocolTitle><Trial id="359917"/><TrialEndDateActual/><TrialEndDateCalc>2020-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-09-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="107803">GamTBvac</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine 'GamTBvac' Against the Tuberculosis</ProtocolTitle><Trial id="309614"/><TrialEndDateActual>2017-12-13 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-05-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-12-13 00:00:00</TrialEndDateGiven><TrialStartDate>2017-01-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="30819">tedizolid phosphate</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single-Doses of Tedizolid Plus Rifampicin in Healthy Volunteers</ProtocolTitle><Trial id="331225"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>2927</Patients><ProtocolTitle>The Correlate of Risk Targeted Intervention Study</ProtocolTitle><Trial id="258043"/><TrialEndDateActual/><TrialEndDateCalc>2019-01-10 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-09-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4027</Patients><ProtocolTitle>Evaluation of the Effect of 3HP versus Periodic 3HP versus 6H in HIV-Positive Individuals</ProtocolTitle><Trial id="281055"/><TrialEndDateActual/><TrialEndDateCalc>2019-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="76307">delpazolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A clinical trial of RMX-2001 in multidrug-resistant tuberculosis (MDR-TB) in USA</ProtocolTitle><Trial id="370698"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients><ProtocolTitle>Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings</ProtocolTitle><Trial id="294801"/><TrialEndDateActual/><TrialEndDateCalc>2019-10-27 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-08-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>530</Patients><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Trial id="228190"/><TrialEndDateActual/><TrialEndDateCalc>2018-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="84564">ChAdOx1-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>72</Patients><ProtocolTitle>EMaBS TB Vaccine Study</ProtocolTitle><Trial id="354327"/><TrialEndDateActual/><TrialEndDateCalc>2021-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-12-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Bioequivalence</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients><ProtocolTitle>Bioequivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions</ProtocolTitle><Trial id="218651"/><TrialEndDateActual>2012-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-06-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="116061">68Ga-tilmanocept</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A comparative study to evaluate the use of 68Ga-tilmanocept in patients with tuberculosis (TB)</ProtocolTitle><Trial id="378644"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>750</Patients><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Trial id="259506"/><TrialEndDateActual/><TrialEndDateCalc>2019-04-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>630</Patients><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Trial id="244304"/><TrialEndDateActual/><TrialEndDateCalc>2019-05-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>238</Patients><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Trial id="247456"/><TrialEndDateActual/><TrialEndDateCalc>2018-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="89744">MTBVAC</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients><ProtocolTitle>MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa</ProtocolTitle><Trial id="275657"/><TrialEndDateActual/><TrialEndDateCalc>2021-05-15 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-15 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-15 00:00:00</TrialEndDateGiven><TrialStartDate>2019-01-24 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4155">pravastatin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>Statin Adjunctive Therapy for TB</ProtocolTitle><Trial id="331728"/><TrialEndDateActual/><TrialEndDateCalc>2021-12-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-01 00:00:00</TrialEndDateGiven><TrialStartDate>2019-08-15 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>183</Patients><ProtocolTitle>Assessing PA-824 for Tuberculosis</ProtocolTitle><Trial id="213394"/><TrialEndDateActual/><TrialEndDateCalc>2017-08-18 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-04-29 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53019">GX-70</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Safety and Immunogenicity Study of GX-70 in TB Patient</ProtocolTitle><Trial id="298965"/><TrialEndDateActual>2018-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2020-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>Pharmacokinetic Study to Evaluate Anti-Mycobacterial Activity of TMC-207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB</ProtocolTitle><Trial id="221523"/><TrialEndDateActual/><TrialEndDateCalc>2018-08-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2025-07-13 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2025-07-13 00:00:00</TrialEndDateGiven><TrialStartDate>2016-05-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients><ProtocolTitle>Shortening Treatment by Advancing Novel Drugs</ProtocolTitle><Trial id="221844"/><TrialEndDateActual>2018-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="13340">everolimus</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>TB Host Directed Therapy</ProtocolTitle><Trial id="279898"/><TrialEndDateActual/><TrialEndDateCalc>2019-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Trial id="319125"/><TrialEndDateActual/><TrialEndDateCalc>2020-11-18 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-07-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3900</Patients><ProtocolTitle>Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis</ProtocolTitle><Trial id="271641"/><TrialEndDateActual/><TrialEndDateCalc>2018-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</ProtocolTitle><Trial id="224811"/><TrialEndDateActual>2015-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-01-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>238</Patients><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Trial id="247456"/><TrialEndDateActual/><TrialEndDateCalc>2018-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients><ProtocolTitle>Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects</ProtocolTitle><Trial id="298711"/><TrialEndDateActual>2017-09-06 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-08-12 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-09-06 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>TASK-002: Bioequivalence of Bedaquiline 400 mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions</ProtocolTitle><Trial id="286376"/><TrialEndDateActual>2017-01-11 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-03-02 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-01-11 00:00:00</TrialEndDateGiven><TrialStartDate>2016-11-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7017">gatifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>140</Patients><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Trial id="328802"/><TrialEndDateActual/><TrialEndDateCalc>2012-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2010-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-12-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>220</Patients><ProtocolTitle>Refining MDR-TB Treatment Regimens for Ultra Short Therapy</ProtocolTitle><Trial id="372676"/><TrialEndDateActual/><TrialEndDateCalc>2021-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-12-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-12-01 00:00:00</TrialEndDateGiven><TrialStartDate>2019-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>125</Patients><ProtocolTitle>A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis</ProtocolTitle><Trial id="353987"/><TrialEndDateActual/><TrialEndDateCalc>2021-02-13 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-10-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Trial id="381674"/><TrialEndDateActual/><TrialEndDateCalc>2021-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2019-08-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>180</Patients><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Trial id="293734"/><TrialEndDateActual/><TrialEndDateCalc>2020-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>250</Patients><ProtocolTitle>Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis</ProtocolTitle><Trial id="374838"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>146</Patients><ProtocolTitle>Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis</ProtocolTitle><Trial id="8791"/><TrialEndDateActual>2008-09-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-02-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-09-01 00:00:00</TrialEndDateGiven><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Trial id="319125"/><TrialEndDateActual/><TrialEndDateCalc>2020-11-18 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-07-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="82091">ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>474</Patients><ProtocolTitle>Appropriate course of the treatment of tuberculous pleurisy</ProtocolTitle><Trial id="309137"/><TrialEndDateActual/><TrialEndDateCalc>2017-09-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2015-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>An open-label, phase I trial to evaluate the safety, tolerability and immunogenicity of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection</ProtocolTitle><Trial id="8497"/><TrialEndDateActual>2007-05-11 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-02-13 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-05-11 00:00:00</TrialEndDateGiven><TrialStartDate>2006-10-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="52139">ofloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>217</Patients><ProtocolTitle>A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)</ProtocolTitle><Trial id="152200"/><TrialEndDateActual/><TrialEndDateCalc>2007-03-17 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2006-01-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2006-01-01 00:00:00</TrialEndDateGiven><TrialStartDate>2004-11-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>72</Patients><ProtocolTitle>Tuberculosis Clinical Trials Consortium Study 35</ProtocolTitle><Trial id="359122"/><TrialEndDateActual/><TrialEndDateCalc>2022-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-02-28 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2019-09-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients><ProtocolTitle>Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic</ProtocolTitle><Trial id="235355"/><TrialEndDateActual/><TrialEndDateCalc>2018-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients><ProtocolTitle>TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer</ProtocolTitle><Trial id="42128"/><TrialEndDateActual>2009-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>5610</Patients><ProtocolTitle>Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients</ProtocolTitle><Trial id="344335"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2025-06-18 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2025-06-18 00:00:00</TrialEndDateGiven><TrialStartDate>2019-06-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3000</Patients><ProtocolTitle>Study for latent tuberculosis infection intervention among close contacts of pulmonary tuberculosis patients</ProtocolTitle><Trial id="361821"/><TrialEndDateActual/><TrialEndDateCalc>2020-09-29 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-06-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>75</Patients><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Trial id="381674"/><TrialEndDateActual/><TrialEndDateCalc>2021-12-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-02-29 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-02-29 00:00:00</TrialEndDateGiven><TrialStartDate>2019-08-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>38</Patients><ProtocolTitle>The safety and efficacy of high dose rifapentine in treatment of tuberculosis</ProtocolTitle><Trial id="359664"/><TrialEndDateActual/><TrialEndDateCalc>2021-04-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-01-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-01-01 00:00:00</TrialEndDateGiven><TrialStartDate>2019-01-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48499">H4:IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>70</Patients><ProtocolTitle>A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-negative, TB-negative, BCG-naive Adults</ProtocolTitle><Trial id="227111"/><TrialEndDateActual>2013-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="104447">OPC-167832</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A multiple-ascending-dose and early-bactericidal-activity study to assess OPC-167832 in drug susceptible TB patients</ProtocolTitle><Trial id="327016"/><TrialEndDateActual/><TrialEndDateCalc>2021-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2018-12-31 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A Phase II Study of H56:IC31 in Healthy Adolescents</ProtocolTitle><Trial id="310653"/><TrialEndDateActual/><TrialEndDateCalc>2020-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2018-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="104447">OPC-167832</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>125</Patients><ProtocolTitle>A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis</ProtocolTitle><Trial id="353987"/><TrialEndDateActual/><TrialEndDateCalc>2021-02-13 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-10-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>84</Patients><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Trial id="243619"/><TrialEndDateActual/><TrialEndDateCalc>2019-01-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-01-15 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-01-15 00:00:00</TrialEndDateGiven><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="69974">cabotegravir</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients><ProtocolTitle>Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects</ProtocolTitle><Trial id="298711"/><TrialEndDateActual>2017-09-06 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-08-12 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-09-06 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4728">emtricitabine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>RIFART</ProtocolTitle><Trial id="131240"/><TrialEndDateActual>2011-04-19 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-05-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-19 00:00:00</TrialEndDateGiven><TrialStartDate>2005-03-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>240</Patients><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in HIV-positive Adults</ProtocolTitle><Trial id="73200"/><TrialEndDateActual>2015-06-04 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-05-08 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-06-04 00:00:00</TrialEndDateGiven><TrialStartDate>2011-01-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>47</Patients><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Trial id="11188"/><TrialEndDateActual>2012-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>780</Patients><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Trial id="10681"/><TrialEndDateActual>2010-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-11-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="2807">atorvastatin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial</ProtocolTitle><Trial id="199754"/><TrialEndDateActual/><TrialEndDateCalc>2016-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients><ProtocolTitle>Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)</ProtocolTitle><Trial id="89135"/><TrialEndDateActual>2017-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-02-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients><ProtocolTitle>Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects</ProtocolTitle><Trial id="208141"/><TrialEndDateActual>2010-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7310">ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>9</Patients><ProtocolTitle>Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin</ProtocolTitle><Trial id="93494"/><TrialEndDateActual>2018-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-05-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>142</Patients><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With Tuberculosis (TB) Disease</ProtocolTitle><Trial id="80383"/><TrialEndDateActual>2014-04-10 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-03-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-04-10 00:00:00</TrialEndDateGiven><TrialStartDate>2011-11-14 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3411">itraconazole</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>A Comparative Study of Itraconazole in Various Doses Schedule in the Treatment of Pulmonary Aspergilloma in Treated  with the Patients of Pulmonary Tuberculosis</ProtocolTitle><Trial id="131456"/><TrialEndDateActual/><TrialEndDateCalc>2014-11-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55317">MVA-85A</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV</ProtocolTitle><Trial id="10868"/><TrialEndDateActual>2010-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-02-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>722</Patients><ProtocolTitle>An open-label, active control trial of rifapentine to evaluate efficacy, in patients with pulmonary tuberculosis</ProtocolTitle><Trial id="15328"/><TrialEndDateActual/><TrialEndDateCalc>2001-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44409">Fluzone</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>301</Patients><ProtocolTitle>Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults</ProtocolTitle><Trial id="116439"/><TrialEndDateActual>2014-11-20 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-06-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-11-20 00:00:00</TrialEndDateGiven><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Trial id="11187"/><TrialEndDateActual>2010-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>39</Patients><ProtocolTitle>A self-controlled, single-center Taiwanese study to assess the efficacy and tolerability of rifabutin for re-treating chronic cases of multidrug-resistant pulmonary tuberculosis</ProtocolTitle><Trial id="15897"/><TrialEndDateActual/><TrialEndDateCalc>1999-04-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>135</Patients><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Trial id="114300"/><TrialEndDateActual>2013-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-09-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>152</Patients><ProtocolTitle>Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide</ProtocolTitle><Trial id="183613"/><TrialEndDateActual/><TrialEndDateCalc>2016-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-04-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals Candidate Tuberculosis (TB) Vaccine GSK-692342</ProtocolTitle><Trial id="90314"/><TrialEndDateActual>2013-05-24 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-12-11 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-05-24 00:00:00</TrialEndDateGiven><TrialStartDate>2012-08-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>65</Patients><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Trial id="71107"/><TrialEndDateActual>2011-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-02-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>28</Patients><ProtocolTitle>A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants</ProtocolTitle><Trial id="59134"/><TrialEndDateActual>2010-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10172">efavirenz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Trial id="76946"/><TrialEndDateActual/><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2013-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2013-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>39</Patients><ProtocolTitle>Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)</ProtocolTitle><Trial id="89135"/><TrialEndDateActual>2017-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-02-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients><ProtocolTitle>A Study to Investigate Pharmacokinetics, Safety and Tolerability of TMC-207 in Patients With Moderately Impaired Hepatic Function</ProtocolTitle><Trial id="61895"/><TrialEndDateActual>2011-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-03-18 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4481">stavudine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>540</Patients><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Trial id="145651"/><TrialEndDateActual>2010-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>RIFART</ProtocolTitle><Trial id="131240"/><TrialEndDateActual>2011-04-19 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-05-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-04-19 00:00:00</TrialEndDateGiven><TrialStartDate>2005-03-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>90</Patients><ProtocolTitle>An Open-Label, Sequential Non-Randomized Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir Superboosted With Ritonavir (1 : 1 Ratio) in the Presence of Rifampicin or Lopinavir Boosted With Ritonavir (4 : 1 Ratio) in the Absence of Rifampicin in HIV and TB Co-Infected Children in South Africa</ProtocolTitle><Trial id="142540"/><TrialEndDateActual/><TrialEndDateCalc>2015-03-23 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2014-07-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2014-07-01 00:00:00</TrialEndDateGiven><TrialStartDate>2012-12-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>Latency in Pulmonary Tuberculosis</ProtocolTitle><Trial id="67984"/><TrialEndDateActual/><TrialEndDateCalc>2012-06-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2015-02-28 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2015-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>66</Patients><ProtocolTitle>Phase I, ID93 + GLA-SE Vaccine Trial in BCG-vaccinated Healthy Adult Volunteers</ProtocolTitle><Trial id="151743"/><TrialEndDateActual>2015-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11088">sutezolid</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>59</Patients><ProtocolTitle>PK and Bactericidal Activity in Sputum and Blood of PNU-100480 (Sutezolid, U-480) and its Major Metabolite (PNU-101603, U-603) in Patients with Pulmonary TB</ProtocolTitle><Trial id="128346"/><TrialEndDateActual>2012-09-12 00:00:00</TrialEndDateActual><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven>2012-09-12 00:00:00</TrialEndDateGiven><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A Study to Evaluate Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected with HIV and TB</ProtocolTitle><Trial id="147644"/><TrialEndDateActual/><TrialEndDateCalc>2014-06-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2015-01-12 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2015-01-12 00:00:00</TrialEndDateGiven><TrialStartDate>2012-01-12 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients><ProtocolTitle>A hospital-based retrospective study to assess the clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China</ProtocolTitle><Trial id="234062"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>74</Patients><ProtocolTitle>Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers</ProtocolTitle><Trial id="90512"/><TrialEndDateActual>2012-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Trial id="230529"/><TrialEndDateActual/><TrialEndDateCalc>2018-02-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>44</Patients><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Trial id="10646"/><TrialEndDateActual/><TrialEndDateCalc>2002-05-02 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2000-02-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>102</Patients><ProtocolTitle>Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB</ProtocolTitle><Trial id="10652"/><TrialEndDateActual>2004-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2001-10-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2002-11-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2004-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>1999-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="11036">linezolid</Drug><Endpoint>Safety</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>Pilot Study Examining the Safety and Tolerability of Low Dose Linezolid in the Treatment of Multi-Drug Resistant Tuberculosis</ProtocolTitle><Trial id="11219"/><TrialEndDateActual>2010-09-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-09-01 00:00:00</TrialEndDateGiven><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8255">nelfinavir</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB</ProtocolTitle><Trial id="10656"/><TrialEndDateActual>2005-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2002-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2002-02-28 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2005-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2000-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7310">ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients><ProtocolTitle>The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin</ProtocolTitle><Trial id="10871"/><TrialEndDateActual>2009-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-03-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2009-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2009-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>18</Patients><ProtocolTitle>Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis</ProtocolTitle><Trial id="11184"/><TrialEndDateActual>2010-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-08-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>69</Patients><ProtocolTitle>Essentiality of INH in TB Therapy</ProtocolTitle><Trial id="87091"/><TrialEndDateActual>2016-02-10 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-10-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-02-10 00:00:00</TrialEndDateGiven><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3700">nevirapine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>116</Patients><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Trial id="10863"/><TrialEndDateActual/><TrialEndDateCalc>2008-11-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2011-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2011-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="11115">IMM-201</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A phase II/III study to evaluate the safety and efficacy of SRL-172 for the treatment of tuberculosis</ProtocolTitle><Trial id="19996"/><TrialEndDateActual/><TrialEndDateCalc>2000-04-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Suspended</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17132">pascolizumab</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>32</Patients><ProtocolTitle>Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis</ProtocolTitle><Trial id="89066"/><TrialEndDateActual/><TrialEndDateCalc>2014-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2017-07-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2017-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>An Open-Label Study to Evaluate the Effects on Mycobacterium Tuberculosis, Safety, Tolerability and Pharmacokinetics of Single Doses of R-207910, in Treatment Naive Patients With Mycobacterium Tuberculosis Infection</ProtocolTitle><Trial id="129536"/><TrialEndDateActual/><TrialEndDateCalc>2007-02-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2004-10-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>36</Patients><ProtocolTitle>A Study to Assess the Relative Bioavailability of TMC-207 Following Single-dose Administrations of Two Pediatric Formulations in Healthy Adult Participants</ProtocolTitle><Trial id="114087"/><TrialEndDateActual>2013-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Trial id="11187"/><TrialEndDateActual>2010-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="14681">lopinavir + ritonavir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>40</Patients><ProtocolTitle>Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw</ProtocolTitle><Trial id="226826"/><TrialEndDateActual/><TrialEndDateCalc>2017-09-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-09-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>121</Patients><ProtocolTitle>Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis</ProtocolTitle><Trial id="23035"/><TrialEndDateActual/><TrialEndDateCalc>2012-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2009-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="71742">TBA-354</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>48</Patients><ProtocolTitle>A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</ProtocolTitle><Trial id="215600"/><TrialEndDateActual>2015-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2015-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81363">AEC/BC02</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>175</Patients><ProtocolTitle>Clinical study of freeze - dried recombinant tuberculosis vaccine (AEC/BC02)</ProtocolTitle><Trial id="291253"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="101474">small molecule therapeutic, Beijing Union Pharmaceutical Factory/Institute of Materia Medica</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>58</Patients><ProtocolTitle>The phase Ia clinical trial of pyrifazimine</ProtocolTitle><Trial id="356451"/><TrialEndDateActual/><TrialEndDateCalc>2021-01-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-10-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>900</Patients><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Trial id="333435"/><TrialEndDateActual/><TrialEndDateCalc>2020-07-10 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-03-12 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-03-12 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46931">cefadroxil</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Trial id="360329"/><TrialEndDateActual/><TrialEndDateCalc>2021-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-05-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-05-30 00:00:00</TrialEndDateGiven><TrialStartDate>2018-11-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3474">lamivudine</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>35</Patients><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Trial id="11187"/><TrialEndDateActual>2010-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-05-06 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="12978">moxifloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Trial id="230529"/><TrialEndDateActual/><TrialEndDateCalc>2018-02-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="90085">macozinone</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>32</Patients><ProtocolTitle>Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ-169 Formulation</ProtocolTitle><Trial id="328144"/><TrialEndDateActual>2018-03-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2020-03-26 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-03-28 00:00:00</TrialEndDateGiven><TrialStartDate>2017-12-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Trial id="244777"/><TrialEndDateActual/><TrialEndDateCalc>2011-01-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2010-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2010-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-10-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="90085">macozinone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>16</Patients><ProtocolTitle>Phase IIa Study of PBTZ-169</ProtocolTitle><Trial id="318771"/><TrialEndDateActual>2018-02-22 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-04-07 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-02-22 00:00:00</TrialEndDateGiven><TrialStartDate>2016-12-16 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>120</Patients><ProtocolTitle>Optimizing Treatment to Improve TBM Outcomes in Children</ProtocolTitle><Trial id="278847"/><TrialEndDateActual/><TrialEndDateCalc>2019-05-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2017-02-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16545">delamanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase III study of delamanid in multidrug-resistant tuberculosis patients</ProtocolTitle><Trial id="323086"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Trial id="280651"/><TrialEndDateActual/><TrialEndDateCalc>2019-12-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2017-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3616">meropenem</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Trial id="220739"/><TrialEndDateActual>2014-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-01-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3492">levofloxacin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>2006</Patients><ProtocolTitle>A randomized, controlled trial of 6 months of daily levofloxacin for the prevention of tuberculosis among household contacts of patients with multi-drug resistant tuberculosis</ProtocolTitle><Trial id="269403"/><TrialEndDateActual/><TrialEndDateCalc>2018-07-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2016-03-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>80</Patients><ProtocolTitle>Research on New Regimens for Retreatment Pulmonary Tuberculosis</ProtocolTitle><Trial id="220243"/><TrialEndDateActual/><TrialEndDateCalc>2015-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients/><ProtocolTitle>A phase I trial to evaluate the safety, tolerability, pharmacokinetics of a single dose of PA-824</ProtocolTitle><Trial id="9416"/><TrialEndDateActual/><TrialEndDateCalc>2007-10-04 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2005-06-14 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="3616">meropenem</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>88</Patients><ProtocolTitle>Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB</ProtocolTitle><Trial id="300655"/><TrialEndDateActual/><TrialEndDateCalc>2019-12-13 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-07-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-08-23 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>230</Patients><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Trial id="334027"/><TrialEndDateActual/><TrialEndDateCalc>2020-08-28 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-04-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4229">rifabutin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="85970">telacebec</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>A Phase II Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q-203)</ProtocolTitle><Trial id="343604"/><TrialEndDateActual/><TrialEndDateCalc>2020-11-11 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-07-23 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="85970">telacebec</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A phase I, singlecenter, open-label, prospective clinical study to assess safety, tolerability and pharmacokinetics of ascending doses of Q-203 in single use in healthy subjects</ProtocolTitle><Trial id="371518"/><TrialEndDateActual>2017-06-22 00:00:00</TrialEndDateActual><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven>2017-06-22 00:00:00</TrialEndDateGiven><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>448</Patients><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Trial id="307654"/><TrialEndDateActual/><TrialEndDateCalc>2019-08-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15102">rifapentine</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>566</Patients><ProtocolTitle>Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis</ProtocolTitle><Trial id="375813"/><TrialEndDateActual/><TrialEndDateCalc>2021-03-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-06-01 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-06-01 00:00:00</TrialEndDateGiven><TrialStartDate>2018-12-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="70901">BTZ-043</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A Single Ascending Dose Study Of BTZ-043</ProtocolTitle><Trial id="346718"/><TrialEndDateActual>2019-03-05 00:00:00</TrialEndDateActual><TrialEndDateCalc>2020-09-26 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2019-03-05 00:00:00</TrialEndDateGiven><TrialStartDate>2018-06-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53975">AERAS-402</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A double-blind, randomized, placebo-controlled, phase I study of AERAS-402, a potential vaccine for Mycobacterium tuberculosis infection</ProtocolTitle><Trial id="8498"/><TrialEndDateActual/><TrialEndDateCalc>2009-08-30 22:47:27</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2007-05-11 10:47:27</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>900</Patients><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Trial id="333435"/><TrialEndDateActual/><TrialEndDateCalc>2020-07-10 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-03-12 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-03-12 00:00:00</TrialEndDateGiven><TrialStartDate>2018-03-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>22</Patients><ProtocolTitle>A Phase I Study of Safety and Immunogenicity of AERAS-456 in HIV-Negative Adults Treated for Drug-susceptible Pulmonary TB</ProtocolTitle><Trial id="223291"/><TrialEndDateActual>2016-10-24 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-03-12 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-10-24 00:00:00</TrialEndDateGiven><TrialStartDate>2014-11-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="74849">SSI H56-IC31</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>84</Patients><ProtocolTitle>Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents</ProtocolTitle><Trial id="223463"/><TrialEndDateActual>2016-12-09 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-09-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-12-09 00:00:00</TrialEndDateGiven><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57308">RUTI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>Clinical Trial to Study Four Different Doses of the Vaccine RUTI in Healthy Volunteers</ProtocolTitle><Trial id="8888"/><TrialEndDateActual>2008-06-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-08-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-06-01 00:00:00</TrialEndDateGiven><TrialStartDate>2007-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>12</Patients><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults</ProtocolTitle><Trial id="23067"/><TrialEndDateActual>2004-12-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-05-22 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2004-12-01 00:00:00</TrialEndDateGiven><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="76307">delpazolid</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients><ProtocolTitle>Phase I study Evaluating the Safety, Tolerability and Pharmacokinetic Characteristics of RMX-2001</ProtocolTitle><Trial id="381962"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="55569">VPM-1002</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>2000</Patients><ProtocolTitle>Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence in India</ProtocolTitle><Trial id="298671"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-05 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-11-20 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-11-20 00:00:00</TrialEndDateGiven><TrialStartDate>2017-12-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44279">amoxicillin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1875</Patients><ProtocolTitle>Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis</ProtocolTitle><Trial id="341686"/><TrialEndDateActual/><TrialEndDateCalc>2021-06-16 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2019-02-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4492">faropenem</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>56</Patients><ProtocolTitle>Synergistically acting Rifampicin and Faropenem in Tuberculosis</ProtocolTitle><Trial id="377088"/><TrialEndDateActual/><TrialEndDateCalc>2021-09-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-05-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="13323">pretomanid</Drug><Endpoint>Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Trial id="379769"/><TrialEndDateActual/><TrialEndDateCalc>2021-10-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-07-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51310">bedaquiline</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>500</Patients><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Trial id="369109"/><TrialEndDateActual/><TrialEndDateCalc>2021-06-27 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-03-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44279">amoxicillin</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>45</Patients><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Trial id="360329"/><TrialEndDateActual/><TrialEndDateCalc>2021-03-21 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-05-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-05-30 00:00:00</TrialEndDateGiven><TrialStartDate>2018-11-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="66409">IMX-461</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults</ProtocolTitle><Trial id="142322"/><TrialEndDateActual>2014-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-11-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4567">etanercept</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>174</Patients><ProtocolTitle>Risk of Tuberculosis and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh</ProtocolTitle><Trial id="337163"/><TrialEndDateActual/><TrialEndDateCalc>2020-03-10 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-01-16 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59062">dolutegravir</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="221">Mycobacterium tuberculosis infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>Efficacy, Safety and Pharmacokinetics of DTG With RIF</ProtocolTitle><Trial id="359086"/><TrialEndDateActual/><TrialEndDateCalc>2021-07-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2021-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2021-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-03-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row></Rowset>